var title_f29_39_30320="Endocervical polyp";
var content_f29_39_30320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endocervical polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A blue speculum has been placed in the vagina. An endocervical polyp can be seen protruding from and obscuring the external cervical os. Blood vessels are visible on the surface of the polyp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30320=[""].join("\n");
var outline_f29_39_30320=null;
var title_f29_39_30321="SIS abn ut bleeding3";
var content_f29_39_30321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saline infusion sonography of a patient with uterine bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Saline infusion sonography of a patient with uterine bleeding reveals fluffy endometrial tissue occupying the right lateral half of the endometrial cavity while the left side is thin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30321=[""].join("\n");
var outline_f29_39_30321=null;
var title_f29_39_30322="Complete uterine prolapse";
var content_f29_39_30322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Evaluation of uterine prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: RG Rogers, MD, Division of Female Pelvic Medicine and Reconstructive Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30322=[""].join("\n");
var outline_f29_39_30322=null;
var title_f29_39_30323="Hyperkyphosis patient";
var content_f29_39_30323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperkyphosis patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marilyn Spievak Brodwick, University of Galveston, TX.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30323=[""].join("\n");
var outline_f29_39_30323=null;
var title_f29_39_30324="Tamsulosin: Patient drug information";
var content_f29_39_30324=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tamsulosin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     see \"Tamsulosin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flomax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ava-Tamsulosin CR;",
"     </li>",
"     <li>",
"      Flomax&reg; CR;",
"     </li>",
"     <li>",
"      JAMP-Tamsulosin;",
"     </li>",
"     <li>",
"      Mylan-Tamsulosin;",
"     </li>",
"     <li>",
"      RAN&trade;-Tamsulosin;",
"     </li>",
"     <li>",
"      ratio-Tamsulosin;",
"     </li>",
"     <li>",
"      Sandoz-Tamsulosin;",
"     </li>",
"     <li>",
"      Sandoz-Tamsulosin CR;",
"     </li>",
"     <li>",
"      Teva-Tamsulosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In men, it is used to treat the signs of an enlarged prostate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat kidney stones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tamsulosin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having cataract surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If taking for an enlarged prostate, have a rectal exam (to check prostate gland) and blood work (PSA test). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes after the same meal every day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11070 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30324=[""].join("\n");
var outline_f29_39_30324=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224754\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224755\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023516\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023518\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023517\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023522\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023523\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023525\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023520\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023521\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023526\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023527\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=related_link\">",
"      Tamsulosin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_39_30325="Chlorpheniramine, phenylephrine, and dextromethorphan: Patient drug information";
var content_f29_39_30325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine, phenylephrine, and dextromethorphan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/60/24517?source=see_link\">",
"     see \"Chlorpheniramine, phenylephrine, and dextromethorphan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardec&trade; DM [OTC];",
"     </li>",
"     <li>",
"      Corfen-DM [OTC];",
"     </li>",
"     <li>",
"      De-Chlor DM [OTC];",
"     </li>",
"     <li>",
"      Ed A-Hist DM [OTC];",
"     </li>",
"     <li>",
"      EndaCof [OTC];",
"     </li>",
"     <li>",
"      Father John's&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PEH DM [OTC] [DSC];",
"     </li>",
"     <li>",
"      nasohist&trade; DM pediatric [OTC];",
"     </li>",
"     <li>",
"      Neo DM [OTC];",
"     </li>",
"     <li>",
"      NoHist DM [OTC];",
"     </li>",
"     <li>",
"      PE-Hist-DM [OTC];",
"     </li>",
"     <li>",
"      Virdec DM [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorpheniramine, phenylephrine, dextromethorphan, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, very bad heart disease, trouble passing urine, ulcer disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11237 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30325=[""].join("\n");
var outline_f29_39_30325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011462\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011464\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011463\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011468\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011469\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011471\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011466\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011467\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011472\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011473\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/60/24517?source=related_link\">",
"      Chlorpheniramine, phenylephrine, and dextromethorphan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_39_30326="Quazepam: Drug information";
var content_f29_39_30326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quazepam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/21/36180?source=see_link\">",
"    see \"Quazepam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypnotic:",
"     </b>",
"     Oral: Initial: 15 mg at bedtime; in some patients, the dose may be reduced to 7.5 mg after a few nights",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing should be cautious; begin at lower end of dosing range (ie, 7.5 mg)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9654277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; monitor for signs of excessive sedation or impaired coordination.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F216209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; monitor for signs of excessive sedation or impaired coordination.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doral&reg;: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F216224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9654275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191086.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191086.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Quazepam may be confused with oxazepam",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Daytime drowsiness (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (5%), dizziness (2%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Xerostomia (2%), dyspepsia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Asterisked (*) reactions are those reported with benzodiazepines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, agitation, amnesia, anxiety, apathy, ataxia, confusion, depression, dystonia*, euphoria, hallucinations*, hyper-/hypokinesia, incoordination, irritability*, malaise, nervousness, nightmare, paranoid reaction, sleep disturbances*, slurred speech*, speech disorder, stimulation*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased, menstrual irregularities*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abnormal taste perception, anorexia, constipation, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence, incontinence, urinary retention*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Jaundice*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria*, muscle spasticity*, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision, cataract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Drug dependence, withdrawal*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis, angioedema, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quazepam, other benzodiazepines, or any component of the formulation; sleep apnea; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Product labeling does not include narrow-angle glaucoma; however, use in narrow-angle glaucoma is contraindicated with other benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; excessive sedation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; excessive sedation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents.  Due to increased sensitivity in this age group and slower metabolism of long-acting agents (such as quazepam), avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Use lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypnotic: Appropriate use: Should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: Quazepam may increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F216203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit juice may decrease the metabolism of quazepam. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may increase the metabolism of quazepam. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5635804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although information specific to the use of quazepam has not been located, all benzodiazepines are assumed to cross the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines. Use during pregnancy is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5635806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quazepam and its metabolites are excreted into breast milk. Approximately 0.1% of the maternal dose is found in breast milk. Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9603936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F216197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Doral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $460.37",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F216186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory status; mental status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dorme (ZA);",
"     </li>",
"     <li>",
"      Dormyl (GR);",
"     </li>",
"     <li>",
"      Prosedar (PT);",
"     </li>",
"     <li>",
"      Quazium (IT);",
"     </li>",
"     <li>",
"      Quiedorm (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms metabolites (active)- 2-oxoquasepam and N-desalkyl-2-oxoquazepam",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum: Quazepam, 2-oxoquasepam: 39 hours; N-desalkyl-2-oxoquazepam: 73 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (31%, only trace amounts as unchanged drug); feces (23%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/39/30326/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/39/30326/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/39/30326/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chung M, Hilbert JM, Gural RP, et al, &ldquo;Multiple Dose Quazepam Kinetics,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1984, 35(4):520-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/39/30326/abstract-text/6705450/pubmed\" id=\"6705450\" target=\"_blank\">",
"        6705450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilbert JM, Gural RP, Symchowicz S, et al, &ldquo;Excretion of Quazepam Into Human Breast Milk,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1984, 24(10):457-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/39/30326/abstract-text/6150944/pubmed\" id=\"6150944\" target=\"_blank\">",
"        6150944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, and Ryals T, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\" Psychiatr Serv, 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/39/30326/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/39/30326/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9842 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30326=[""].join("\n");
var outline_f29_39_30326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216204\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216205\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216222\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216207\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216208\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9654277\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216209\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216189\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216174\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216224\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9654275\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216190\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216228\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216220\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216194\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216178\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216217\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216182\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216203\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216183\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635804\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216211\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635806\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603936\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216197\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216186\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216198\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216177\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216193\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9842\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9842|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/21/36180?source=related_link\">",
"      Quazepam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_39_30327="Anticoagulant and antiplatelet therapy in patients with brain tumors";
var content_f29_39_30327=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulant and antiplatelet therapy in patients with brain tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30327/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30327/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30327/contributors\">",
"     Eudocia Quant Lee, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30327/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30327/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30327/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30327/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/39/30327/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and treatment of venous thromboembolism (VTE) in patients with primary and metastatic brain tumors is complicated by two conflicting issues. Patients with brain tumors have a substantial risk for developing VTE due to a hypercoagulable state, neurosurgical procedures, and often leg paresis. However, there is concern that antithrombotic agents can precipitate hemorrhage into the tumor with neurological worsening.",
"   </p>",
"   <p>",
"    The balance between these issues is discussed here. The overall risk, diagnosis, and treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated ICH are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK OF THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary or metastatic brain tumors, as well as malignancies at other sites, have a latent hypercoagulable state that predisposes to thromboembolism, particularly in the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial small studies suggested a VTE incidence of approximately 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] or even higher [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/6\">",
"     6",
"    </a>",
"    ]. A lower rate was observed in a retrospective analysis of 9489 patients with malignant gliomas identified in a cancer registry in which there were 715 cases of VTE (7.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/2\">",
"     2",
"    </a>",
"    ]. In this study, detection of VTE was based on linkage of hospital discharge codes and probably underestimates the clinical frequency. More than one-half of VTE episodes were diagnosed within two months after a major neurosurgical intervention. A prospective study observed an 18 percent incidence of symptomatic VTE in patients with malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/7\">",
"     7",
"    </a>",
"    ]. Similarly, an incidence of 17 percent was reported in the PRODIGE trial of patients with malignant gliomas who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is clustering of venous thromboembolic events in the postoperative period following craniotomy and during intensive chemotherapy, the risk persists throughout the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/3\">",
"     3",
"    </a>",
"    ]. Risk factors for venous thromboembolism in brain tumor patients may include age &ge;60 years, glioblastoma histology, large tumor size, subtotal resection, use of chemotherapy, neurosurgery with the past two months, the presence of leg paresis, and A or AB blood type [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/2,3,9,10\">",
"     2,3,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATING THE RISK OF BLEEDING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overall bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation should generally be avoided in the presence of prior intracranial bleeding, preexisting bleeding diathesis (eg, platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL),",
"    </span>",
"    or coagulopathy, and should be used with caution in those determined to be at high risk for bleeding after the use of anticoagulants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Known intracerebral tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of inducing bleeding within the tumor, causing neurologic deterioration, raises concerns about the use of anticoagulants or antiplatelet agents in patients known to have brain tumors. Assessing the risk of this potential complication is made more difficult by the possibility of spontaneous tumor hemorrhage that may vary significantly among different tumor types.",
"   </p>",
"   <p>",
"    Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency of symptomatic bleeding into gliomas averages 2 to 4 percent in the absence of antithrombotic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/9\">",
"       9",
"      </a>",
"      ]. Estimates of the frequency of symptomatic intracranial hemorrhage involving other types of primary brain tumors are less reliable; pituitary adenomas are especially prone to spontaneous intratumor hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma have particularly high propensities for spontaneous hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/12\">",
"       12",
"      </a>",
"      ], while brain metastases from other primary tumors (eg, lung, breast) generally do not bleed spontaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Systemic malignancy without known brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of inducing intracerebral bleeding in a cancer patient with occult brain metastases raises questions about whether or not such patients should undergo brain imaging prior to the use of antiplatelet agents or anticoagulants.",
"   </p>",
"   <p>",
"    There are no firm data that resolve these questions. Our approach is based upon the risk of brain metastasis being present and the likelihood of such metastases to bleed following the use of such agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest brain imaging, preferably with MRI, for patients whose primary malignancy is melanoma, small cell carcinoma of the lung, choriocarcinoma, renal cell, breast, adenocarcinoma of the lung, or thyroid cancer. Patients with other systemic cancers should also be imaged if there are any symptoms suggesting brain metastasis (eg, headache, mental status changes, seizures, other neurologic symptoms).",
"     </li>",
"     <li>",
"      The detection of occult metastases is a relative contraindication to anticoagulation, and the risks of hemorrhage must be balanced against the potential benefits. In particular, anticoagulation should be avoided for tumors with a propensity to bleed (renal cell carcinoma, choriocarcinoma, melanoma, thyroid cancer). For patients with occult metastases from other primary tumors, the indication for anticoagulation (eg, stroke prophylaxis in atrial fibrillation, acute pulmonary embolus, deep vein thrombosis) must be weighed against the risk of hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, patients with primary or metastatic brain tumors and VTE were often managed with the placement of inferior vena cava (IVC) filters rather than with anticoagulation because of concern over an increased risk of symptomatic intratumor hemorrhage. However, anticoagulation is now generally preferred because the incidence of complications with IVC filters is much higher than originally thought, and the risk of hemorrhage secondary to anticoagulation is not as high as originally feared [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The relatively low incidence of intratumoral hemorrhage is a particularly important issue for patients who need anticoagulation for reasons other than VTE (eg, atrial fibrillation) in whom there is no role for an IVC filter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inferior vena cava filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of IVC filters in patients with brain tumors has been associated with substantial complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. As an example, in a series of 42 such patients, 12 percent had recurrent pulmonary emboli and 57 percent developed IVC or filter thrombosis, recurrent deep vein thrombosis, or post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/13\">",
"     13",
"    </a>",
"    ]. These complications severely reduced the quality of life of the affected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Warfarin anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies have suggested that, outside of the perioperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/18\">",
"     18",
"    </a>",
"    ], the risk of tumor-associated intracranial hemorrhage may not be significantly increased in patients with primary or metastatic brain tumors if the degree of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is carefully controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/9,13,14,17,19-21\">",
"     9,13,14,17,19-21",
"    </a>",
"    ]. The following observations reflect the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 2 of 103 patients (1.9 percent) with high grade glioma receiving anticoagulation for VTE developed symptomatic intratumoral hemorrhage, a rate almost identical to that among 272 glioma patients without VTE and anticoagulation (2.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 51 patients with known brain metastases and VTE, three (7 percent) developed intracranial hemorrhage, two of whom had supratherapeutic anticoagulation by conventional laboratory criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although randomized comparisons are not available in brain tumor patients, indirect comparisons from case series suggest that carefully controlled oral anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is reasonably safe and associated with fewer serious complications than routine use of IVC filters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to oral anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , there is less experience with low molecular weight (LMW)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for the treatment or prevention of VTE in patients with primary or secondary brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. There are two main issues related to the use of LMW heparin: safety and comparative efficacy to warfarin.",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the primary concern is the potential for an increased risk of intracranial hemorrhage. In a large retrospective series of 203 cancer patients with symptomatic VTE that included 45 with brain metastases, only one patient had an intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/25\">",
"     25",
"    </a>",
"    ]. Multivariate analysis indicated that the presence of brain metastases was not associated with an increased risk of major bleeding.",
"   </p>",
"   <p>",
"    Although one small randomized trial found an increased risk of intracranial hemorrhage when LMW was started prior to surgery for brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/24\">",
"     24",
"    </a>",
"    ], a much larger study involving over 300 patients undergoing elective neurosurgery did not find any increased risk of hemorrhage when LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was begun within 24 hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Warfarin versus LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that have directly compared LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation specifically in patients with brain tumors. From a safety perspective, the risk of intracranial hemorrhage with both approaches appears low based upon the observational studies described above (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Warfarin anticoagulation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Low molecular weight heparin'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was compared to oral anticoagulation in the randomized CLOT trial that included 673 patients with VTE. This trial was not designed to assess the risk of intracranial hemorrhage, and the study included only 34 patients with primary brain tumors and an unknown number with brain metastases. Overall, LMW heparin was more effective than oral anticoagulation in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding. The results of the CLOT trial comparing are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=see_link&amp;anchor=H513254#H513254\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\", section on 'CLOT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional advantages of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    include the lack of interaction with other drugs as well as the convenience of not having to monitor the level of anticoagulation on a regular basis. However, LMW is substantially more expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The issues of choosing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H18#H18\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Treatment of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of VTE requires a balance between the effectiveness of the treatment and the risk of intracranial hemorrhage and other side effects. Because of the high rate of complications associated with placement of an IVC filter, we recommend anticoagulation for six months in all patients except those with tumors that have a high rate of intracranial hemorrhage (ie, metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma). We prefer LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    because of its increased effectiveness in preventing recurrent thromboembolism, the lack of interaction with other drugs, and the convenience of not having to monitor the level of anticoagulation on a regular basis.",
"   </p>",
"   <p>",
"    For patients with brain metastases from tumors that have an increased risk of hemorrhage (ie, metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma), we suggest placement of an IVC filter if there is significant residual metastatic disease in the brain. For patients whose metastatic disease has been surgically removed or treated effectively and for those who are too unstable for placement of an IVC filter, we suggest anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION OF VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the prevention of VTE in at-risk patients with brain tumor, long-term treatment with daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (eg, 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally) may offer partial protection and is easy to administer, although neither the safety nor efficacy of this approach has been well defined in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/21\">",
"     21",
"    </a>",
"    ]. For general VTE prevention, aspirin appears to have some activity, but it is clearly less than that afforded by anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    therapy may be considered for primary prevention of VTE in brain tumor patients who are &ge;60 years old, have large tumors or substantial leg weakness, or are undergoing chemotherapy. However, the effect of aspirin in inhibiting platelet function in patients at risk for chemotherapy-induced thrombocytopenia must be weighed against the limited evidence of benefit in preventing VTE.",
"   </p>",
"   <p>",
"    Primary prophylaxis with anticoagulants is not generally recommended in patients with brain tumors except in the perioperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/23\">",
"     23",
"    </a>",
"    ]. Perioperatively, the frequency of VTE is high [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/2,28\">",
"     2,28",
"    </a>",
"    ], and the use of pneumatic compression stockings combined with LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or unfractionated heparin (5000 units every 12 hours, started 24 hours after surgery) is effective and relatively safe [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/26,29-32\">",
"     26,29-32",
"    </a>",
"    ]. The use of compression stockings should be continued until the patient resumes ambulation.",
"   </p>",
"   <p>",
"    The extended use of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    ) as primary prophylaxis of VTE in patients with newly diagnosed malignant glioma was assessed in the PRODIGE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/8\">",
"     8",
"    </a>",
"    ]. The trial was terminated prematurely because of the unavailability of placebo. Overall, 186 patients were randomly assigned to six months of treatment with dalteparin or placebo, with an option to continue on study medication for up to 12 months. The incidence of clinically-evident VTE at six months was lower among those receiving dalteparin (11 versus 17 percent with placebo), but the difference was not statistically significant. Intracranial hemorrhages were more common in patients treated with dalteparin (5 versus 1 percent with placebo at 12 months).",
"   </p>",
"   <p>",
"    The PRODIGE trial confirmed the substantial risk of VTE in patients with malignant gliomas. Although there were trends toward reduction of VTE and increase in intracranial hemorrhage, the trial did not have adequate statistical power at the time of termination to draw definitive conclusions about the benefits versus risks of long-term anticoagulation.",
"   </p>",
"   <p>",
"    A recent phase II trial involving 40 patients with malignant gliomas treated with the LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    4500 IU subcutaneously daily for a median of about five months reported symptomatic CNS hemorrhage in one (2.5 percent) patient and DVT in one (2.5 percent) patient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H212239249\">",
"    <span class=\"h1\">",
"     BEVACIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a monoclonal antibody that binds to vascular endothelial growth factor and is now use for treatment of malignant glioma in combination with chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    &nbsp;is associated with both an increased risk of bleeding into the primary tumor and VTE.",
"   </p>",
"   <p>",
"    Limited data in patients with malignant glioma who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and anticoagulation suggest that although the risk of ICH is increased in patients receiving anticoagulants compared with those who are not, the risk-to-benefit ratio favors concurrent therapy in many cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=see_link&amp;anchor=H530204220#H530204220\">",
"     \"Management of recurrent malignant gliomas\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with brain metastases, there does not appear to be a significant increase in the risk of hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1651227407#H1651227407\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intracranial bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend anticoagulation in all patients with brain tumors and venous thromboembolism (VTE) except those that have a high rate of intracranial hemorrhage (ie, metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma). (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). VTE in low-grade glioma and benign tumors should be treated for three to six months. Long-term anticoagulation is recommended for malignant gliomas. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of VTE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for anticoagulation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Warfarin versus LMW heparin'",
"      </a>",
"      above.) and \" (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with brain tumors that have an increased risk of hemorrhage (ie, metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma), we suggest placement of an IVC filter if there is significant residual metastatic disease in the brain (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients whose metastatic disease has already been surgically removed or treated effectively and for those whose medical condition is too unstable for placement of an IVC filter, we suggest anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of VTE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prophylaxis of VTE",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although patients with primary or metastatic brain tumors are at relatively high risk for the development of VTE, we suggest that these patients not be anticoagulated, except in the postoperative period (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention of VTE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients undergoing surgery, we suggest the use of pneumatic compression stockings combined with postoperative LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or unfractionated heparin beginning 12 to 24 hours after surgery and continuing until ambulation is resumed (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention of VTE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are consistent with the American Society of Clinical Oncology (ASCO) guidelines for the prevention and treatment of venous thromboembolism in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30327/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/1\">",
"      Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006; 24:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/2\">",
"      Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/3\">",
"      Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/4\">",
"      Kayser-Gatchalian MC, Kayser K. Thrombosis and intracranial tumors. J Neurol 1975; 209:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/5\">",
"      Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 2007; 9:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/6\">",
"      Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol 1992; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/7\">",
"      Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/8\">",
"      Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/9\">",
"      Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/10\">",
"      Streiff MB, Segal J, Grossman SA, et al. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004; 100:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/11\">",
"      Wakai S, Yamakawa K, Manaka S, Takakura K. Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 1982; 10:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/12\">",
"      Mandybur TI. Intracranial hemorrhage caused by metastatic tumors. Neurology 1977; 27:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/13\">",
"      Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/14\">",
"      Olin JW, Young JR, Graor RA, et al. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med 1987; 147:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/15\">",
"      Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002; 14:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/16\">",
"      Norris LK, Grossman SA. Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol 1994; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/17\">",
"      Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/18\">",
"      Brosnan C, Razis P. Complications of treatment: pulmonary embolism following craniotomy for meningioma. J Neurosurg Anesthesiol 1999; 11:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/19\">",
"      Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 1987; 66:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/20\">",
"      Altschuler E, Moosa H, Selker RG, Vertosick FT Jr. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990; 27:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/21\">",
"      Quevedo JF, Buckner JC, Schmidt JL, et al. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994; 69:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/22\">",
"      Goldschmidt N, Linetsky E, Shalom E, et al. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003; 98:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/23\">",
"      Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 2002; 249:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/24\">",
"      Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998; 43:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/25\">",
"      Monreal M, Zacharski L, Jim&eacute;nez JA, et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 2:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/26\">",
"      Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/27\">",
"      Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/28\">",
"      Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis 1999; 8:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/29\">",
"      Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/30\">",
"      Turpie AG, Gallus A, Beattie WS, Hirsh J. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology 1977; 27:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/31\">",
"      Constantini S, Kanner A, Friedman A, et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg 2001; 94:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/32\">",
"      Gerber DE, Segal JB, Salhotra A, et al. Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis. Cancer 2007; 109:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/33\">",
"      Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30327/abstract/34\">",
"      Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5201 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30327=[""].join("\n");
var outline_f29_39_30327=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK OF THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATING THE RISK OF BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overall bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Known intracerebral tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Systemic malignancy without known brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inferior vena cava filters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Warfarin anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Warfarin versus LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION OF VTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212239249\">",
"      BEVACIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prophylaxis of VTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_39_30328="Adult ear";
var content_f29_39_30328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Anatomy of the adult ear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30328=[""].join("\n");
var outline_f29_39_30328=null;
var title_f29_39_30329="Evaluation of weight loss in infants over six months of age, children, and adolescents";
var content_f29_39_30329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of weight loss in infants over six months of age, children, and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30329/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30329/contributors\">",
"     Derya Caglar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30329/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30329/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30329/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/39/30329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5454716\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of weight loss throughout childhood. Dehydration, infection (especially viral gastroenteritis), malnutrition, and child neglect are common causes in older infants and young children. Depression, eating disorders, inflammatory bowel disease, malignancy, and malabsorption (eg, lactose intolerance, celiac disease) are more frequent in school-age children and adolescents. Assessments of the degree and acuity of the weight loss along with specific historical and physical findings should guide the evaluation of these patients.",
"   </p>",
"   <p>",
"    This topic will discuss the approach to weight loss in the older infant and adolescent. Weight loss in young infants is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25288663\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss may be classified as intentional or unintentional. Acute or progressive unintentional weight loss often indicates a serious medical illness that requires evaluation and treatment. Intentional weight loss in overweight or obese individuals is benign in most instances but must be followed closely in the pediatric patient to insure the patient has appropriate growth. The frequency of intentional loss in association with altered body image or other psychiatric illness (eg, anorexia nervosa) increases with advancing age, peaking in adolescence and early adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454723\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major components of body weight consist of water, protein, carbohydrates, and fats. Weight loss occurs when the intake of one or several of these components becomes less than the output. Causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased calorie intake either voluntary (eg, eating disorder) or due to intercurrent illness with normal or increased metabolic expenditure",
"     </li>",
"     <li>",
"      Normal calorie intake with increased metabolic utilization (eg, hyperthyroidism, excessive exercise)",
"     </li>",
"     <li>",
"      Normal or increased calorie intake in the setting of malabsorption or excessive loss of nutrients (eg, inflammatory bowel disease, diabetes mellitus, celiac disease, or self-induced losses [purging by vomiting, diuretics, or laxative use])",
"     </li>",
"     <li>",
"      Acute fluid losses that exceed intake during acute illnesses, such as gastroenteritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454730\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for weight loss in the older infant, child, and adolescent is wide and may require an extensive work-up (",
"    <a class=\"graphic graphic_table graphicRef87727 \" href=\"UTD.htm?32/6/32876\">",
"     table 1",
"    </a>",
"    ). In many cases a diagnosis is not revealed during initial care but the evaluation may begin and specialist referrals can be made as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454737\">",
"    <span class=\"h2\">",
"     Life threatening conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454745\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with new onset diabetes mellitus may present with significant weight loss in the setting of polyuria and polydipsia over days to weeks. Laboratory studies show hyperglycemia and glycosuria. Weight loss is a result of hypovolemia (due to a hyperglycemia-induced osmotic diuresis) and increased catabolism. Insulin deficiency impairs glucose utilization in skeletal muscle and increases fat and muscle breakdown. Initially appetite is increased, but over time, children may become anorexic, contributing to weight loss. Patients may also present with significant illness due to diabetic ketoacidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\", section on 'Classic new onset'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454752\">",
"    <span class=\"h3\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with adrenal insufficiency may present with excessive fluid losses and hemodynamic instability due to a deficiency of corticosteroid production which leads to altered fluid and salt balance. Primary adrenal insufficiency (Addison disease) occurs when the adrenal gland itself is dysfunctional while secondary or tertiary (central) adrenal insufficiency occurs when there is a lack of adrenocorticotropic hormone (ACTH) from the pituitary or corticotropin-releasing hormone (CRH) from the hypothalamus , respectively, that leads to inadequate adrenal function (eg, hypopituitarism, diencephalic syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of adrenal insufficiency in children\", section on 'Primary versus secondary and tertiary adrenal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients suffering from adrenal insufficiency present with vomiting, anorexia, dehydration, and weight loss which can lead to cardiovascular collapse. Physical findings may include hyperpigmentation, especially on the extensor surfaces, and weakness. Hyponatremia, hyperkalemia, hypoglycemia, and metabolic acidosis are classic laboratory findings in the initial assessment. Stabilization involves management of airway, breathing and circulation with a focus on volume resuscitation and corticosteroid replacement. &nbsp;Whenever possible, measurement of serum cortisol should precede corticosteroid administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27238?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes and clinical manifestations of central adrenal insufficiency in children\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=see_link\">",
"     \"Treatment of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454766\">",
"    <span class=\"h3\">",
"     Eating disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with anorexia nervosa typically present with a refusal to maintain body weight at or above a minimally normal weight for age and height defined as either 85 percent of that expected for age and height or a body mass index (BMI) &le;17.5 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Additional features include an intense fear of gaining weight or becoming fat despite being underweight, distorted perception of body weight and shape, and, in postmenarchal females, amenorrhea (",
"    <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"     table 2",
"    </a>",
"    ). Bulimia nervosa is characterized by recurrent episodes of binge eating and inappropriate compensatory behavior to prevent weight gain, occurring on average at least two times per week for three months. Other clinical features options of anorexia nervosa and bulimia nervosa are discussed separately. In severe eating disorders, patients may develop profound bradycardia or electrolytes abnormalities that are life threatening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H5206194#H5206194\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Diagnosis of anorexia nervosa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4101546\">",
"    <span class=\"h3\">",
"     Dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe dehydration from acute gastroenteritis or other illnesses with significant fluid losses can lead to weight loss and hemodynamic compromise. Children with acute gastroenteritis typically present with acute onset of diarrhea, vomiting, fever, anorexia, and abdominal cramps. Blood or mucous in the stool or rice water stool suggest bacterial enteritis or cholera, respectively. Findings of significant dehydration (eg, prolonged capillary refill, dry mucous membranes, lethargy) are commonly found on physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repletion of fluid losses and management of gastroenteritis are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation of diarrhea in children\", section on 'Algorithmic approach to the patient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454787\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2085889\">",
"    <span class=\"h3\">",
"     Viral gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate weight loss commonly accompanies viral gastroenteritis. Clinical manifestations include nonbloody watery diarrhea, nonbilious vomiting, variable fever, abdominal pain, and anorexia. The diagnosis of acute viral gastroenteritis is made clinically. Testing for specific viruses usually is not necessary in immunocompetent hosts with routine gastroenteritis. However, it may be indicated during outbreaks of gastroenteritis, to make decisions about specific therapy, and for cohorting and isolation of hospitalized patients. Most previously healthy patients recover uneventfully but severe dehydration may rarely occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4101546\">",
"     'Dehydration'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12161442\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic weight loss may be a neurovegetative sign of depression, especially in adolescents. Other findings may include decreased appetite, change in sleep, and lack of energy (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ). Problems with school work, drug use, and risky sexual behaviors are additional comorbidities. Recognition of depression can be difficult due to nonspecific complaints and symptoms. In addition to neurovegetative signs described above, depressed school-age children may also present with irritability, generalized body pains, sleep disturbances, headaches, and poor oral intake with associated weight loss. Additional features suggesting depression in older children or adolescents include chronic disease (eg, diabetes mellitus or cancer), a family history of depression in siblings or a parent, and situational stressors. Diagnosis should be based upon a formal clinical interview with the patient that is supplemented by information from parents and, in the primary care setting, from teachers. All patients with signs of depression warrant screening for suicidal ideation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link&amp;anchor=H5#H5\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\", section on 'Classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link&amp;anchor=H17#H17\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454780\">",
"    <span class=\"h3\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis (UC) and Crohn's disease (CD) make up the disorders of inflammatory bowel disease. UC affects the colon, whereas CD can involve any component of the gastrointestinal (GI) tract from the oral cavity to the anus. The peak incidence of IBD occurs in patients between the ages of 15 and 25 years. Approximately 25 to 30 percent of patients with CD and 20 percent of patients with UC present before the age of 20 years. Adolescents and children with IBD may present with oral lesions (eg, mucogingivitis or deep ulcerations), abdominal pain, weight loss, tenesmus, perianal fistulas or skin tags, diarrhea, and hematochezia. Growth failure and delayed puberty are present in about 30 percent of children and is due to a combination of anorexia and increased energy needs related to inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454795\">",
"    <span class=\"h3\">",
"     Acute infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with underlying acute infections, such as urinary tract infection, pneumonia, or bacterial pharyngitis, can present with weight loss due to decreased ability or desire to feed in conjunction with increased metabolic needs. Fever is frequently present along with other clinical findings that provide clues to the source of infection (eg, cough and respiratory distress [pneumonia], suprapubic or costovertebral angle tenderness [urinary tract infection], sore throat with tonsillar exudate or swelling [streptococcal pharyngitis, peritonsillar abscess]) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30329/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454809\">",
"    <span class=\"h3\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is a multifactorial, autoimmune disorder that occurs in genetically susceptible individuals.",
"    <sup>",
"    </sup>",
"    It is triggered by a well-identified environmental factor (gluten and related prolamins). The disease primarily affects the small intestine, where it progressively leads to flattening of the small intestinal mucosa. Three cereals contain gluten and are toxic for patients with celiac disease: wheat, rye, and barley. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical form of celiac disease presents with GI symptoms that characteristically appear at age 9 to 24 months. Infants and young children typically present with chronic diarrhea, anorexia, abdominal distension, abdominal pain, poor weight gain or weight loss, and vomiting after the introduction of gluten-containing foods. Severe malnutrition can occur if the diagnosis is delayed. Behavioral changes are common and include irritability and an introverted attitude. Rarely, severely affected infants present with a celiac crisis, which is characterized by explosive watery diarrhea, marked abdominal distension, dehydration, hypotension, and lethargy, often with profound electrolyte abnormalities, including severe hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454816\">",
"    <span class=\"h3\">",
"     Child neglect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child neglect is the most prevalent form of child abuse, accounting for more than one-half of cases reported to child protection services. It is defined by the National Center of Child Abuse and Neglect as failure to provide for a child's basic physical, emotional, educational, or medical needs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link&amp;anchor=H3#H3\">",
"     \"Child neglect and emotional abuse\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The manifestations of child neglect include starvation or dehydration due to inadequate provision of food and water; poor hygiene of a child's body; severe, untreated dental caries; failure to provide routine health care including immunizations, and physical abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30329/abstract/2\">",
"     2",
"    </a>",
"    ]. Many but not all children will have physical signs of abuse including fractures and bruises. Often children also suffer from ongoing emotional abuse in conjunction with physical abuse or neglect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454823\">",
"    <span class=\"h3\">",
"     Malnutrition and failure to thrive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate access to food affects a large number of children, especially in the developing world. Severe protein-energy malnutrition is associated with one of two classical syndromes, marasmus (wasting syndrome) and kwashiorkor, or with manifestations of both. Each type of protein-energy malnutrition may be classified as acute or chronic, depending upon the duration of nutritional deprivation. Children with acute malnutrition appear wasted, whereas children with chronic malnutrition have stunted linear growth. A detailed social history can often reveal poverty and economic stressors as potential contributors to weight loss from lack of resources. Patients may present with weight loss or poor weight gain because of decreased intake due to the inability to acquire adequate amounts of nutrition and chronic conditions that are due to poor food availability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30329/abstract/3\">",
"     3",
"    </a>",
"    ]. Often, patients have no reliable housing, schooling, and other social support issues that need to be addressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=see_link&amp;anchor=H6#H6\">",
"     \"Malnutrition in developing countries: Clinical assessment\", section on 'Assessment of severity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to thrive (FTT) is a sign that describes a particular problem, rather than a diagnosis. The term FTT is used to describe instances of growth failure, or more specifically, failure to gain weight appropriately, especially in children three years of age and younger. In more severe cases, linear growth and head circumference also may be affected. A wide variety of medical problems and psychosocial stressors can contribute to FTT (",
"    <a class=\"graphic graphic_table graphicRef69846 \" href=\"UTD.htm?29/12/29901\">",
"     table 4",
"    </a>",
"    ). However, the underlying cause is always related to inadequate nutrition. Several definitions of failure to thrive exist. All definitions identify children with failure to thrive as having low weight in relation to age or length",
"    <strong>",
"     or",
"    </strong>",
"    insufficient weight gain over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\", section on 'Failure to thrive'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2085988\">",
"    <span class=\"h3\">",
"     Lactose intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactose malabsorption may occur as a primary condition or may complicate other conditions, such as inflammatory bowel disease (especially Crohn&rsquo;s disease), celiac disease, and giardiasis (",
"    <a class=\"graphic graphic_table graphicRef71595 \" href=\"UTD.htm?12/0/12299\">",
"     table 5",
"    </a>",
"    ). Characteristics symptoms after the ingestion of lactose include abdominal pain, bloating, flatulence, diarrhea, and, particularly in adolescents, vomiting. The abdominal pain may be crampy in nature and is often localized to the periumbilical area or lower quadrant. Borborygmi may be audible on physical examination and to the patient. The stools are usually bulky, frothy, and watery. Undiagnosed patients who continue with lactose intake may have significant weight loss. Lactose malabsorption should be confirmed by a test of absorption (eg, lactose absorption test) or malabsorption (lactose breath hydrogen test). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link&amp;anchor=H10#H10\">",
"     \"Lactose intolerance\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link&amp;anchor=H12#H12\">",
"     \"Lactose intolerance\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2086096\">",
"    <span class=\"h3\">",
"     Drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia with weight loss may accompany use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and other amphetamines for the treatment of attention deficit disorder with hyperactivity. Administering the medicine at or after a meal, encouraging the ingestion of nutrient dense foods, and offering foods that the child likes for lunch (the meal most likely to be affected) may overcome decreased appetite. If stimulant therapy is associated with growth failure that crosses two major percentiles (ie, the 5",
"    <sup>",
"     th",
"    </sup>",
"    , 10",
"    <sup>",
"     th",
"    </sup>",
"    , 25",
"    <sup>",
"     th",
"    </sup>",
"    , 50",
"    <sup>",
"     th",
"    </sup>",
"    , 75",
"    <sup>",
"     th",
"    </sup>",
"    , 90",
"    <sup>",
"     th",
"    </sup>",
"    , and 95",
"    <sup>",
"     th",
"    </sup>",
"    ), then a drug holiday may be beneficial as long as marked impairment in psychological functioning does not occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2166605#H2166605\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Managing stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454830\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of less common but important conditions may present or be associated with weight loss as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Malignancy",
"      </strong>",
"      &ndash; Patients with continued, unintentional weight loss in the setting of anemia, pallor, bruising, body pains, unexplained fevers, or fatigue may have an underlying malignancy. Although childhood cancers are rare events, they are the fourth leading cause of death in individuals between 1 and 19 years of age in the United States after unintentional injury, homicide, and suicide. Common sites include blood and bone marrow, brain, bone, lymph nodes, nervous system, kidneys, and soft tissues. A thorough physical examination may reveal additional worrisome findings, such as lymphadenopathy or hepatosplenomegaly that constitute need for further evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"       \"Clinical assessment of the child with suspected cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tuberculosis",
"      </strong>",
"      &ndash; Though a rare cause of unexplained weight loss in children and adolescents in resource-rich countries, tuberculosis should be considered in patients presenting with weight loss and chronic cough or respiratory symptoms with fevers lasting more than three weeks. A thorough exposure history should evaluate for any international travel, close adult contacts born in endemic areas, contact with incarcerated individuals, or any history of having been homeless. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link&amp;anchor=H4#H4\">",
"       \"Tuberculosis disease in children\", section on 'United States epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link&amp;anchor=H5#H5\">",
"       \"Tuberculosis disease in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Human immunodeficiency virus",
"      </strong>",
"      &ndash; Clinical manifestations of human immunodeficiency virus (HIV) infection in children and adolescents are varied and nonspecific. Patients may present with recurrent unexplained infections leading to gradual weight loss. Furthermore, loss of lean body mass or wasting is a well-recognized AIDS-defining condition for children and adolescents. HIV infection, opportunistic infections, and increased metabolic demands all can lead to loss of weight and lean body mass. In children, wasting can severely impact normal growth and development and is associated with a high risk for HIV disease progression and short-term mortality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840505#H18840505\">",
"       \"Natural history and classification of pediatric HIV infection\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840533#H18840533\">",
"       \"Natural history and classification of pediatric HIV infection\", section on 'Wasting syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In children and adolescents with possible or established HIV infection, a thorough social and sexual history should explore risk factors, including history of blood transfusions, homelessness, having an HIV-infected parent, sexual contacts, intravenous drug use, and incarceration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31749?source=see_link\">",
"       \"Epidemiology of pediatric HIV infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1737?source=see_link\">",
"       \"The adolescent with HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Primary immunodeficiency",
"      </strong>",
"      &ndash; Children with primary immunodeficiency often have poor weight gain or even weight loss. This is particularly true in the presence of oral ulcers, candidiasis, or chronic diarrhea. Almost three-fourths of the primary immunodeficiencies are caused by an antibody (B cell) deficiency or a combined antibody plus cellular (T cell) abnormality (",
"      <a class=\"graphic graphic_figure graphicRef80845 \" href=\"UTD.htm?8/31/8703\">",
"       figure 1",
"      </a>",
"      ). Isolated T cell defects, as well as phagocytic cell, complement, and other innate immune defects, are much less common. Thus, B cell (antibody) or combined B and T cell diseases should be considered initially, unless clinical features suggest otherwise. Recurrent infections comprise the most common clinical findings. The type and pattern of recurring infections depend on which components of the immune system are affected (",
"      <a class=\"graphic graphic_table graphicRef74045 \" href=\"UTD.htm?3/4/3149\">",
"       table 6",
"      </a>",
"      ). Infection severity also varies, ranging from mild respiratory infections to overwhelming systemic infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link&amp;anchor=H5015731#H5015731\">",
"       \"Approach to the child with recurrent infections\", section on 'Clinical features suggestive of a primary immunodeficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other chronic infections",
"      </strong>",
"      &ndash; Several chronic infections may cause weight loss in association with prolonged fever and nonspecific and variable clinical findings, such as lymphadenopathy, hepatitis, and myalgias including brucellosis, leptospirosis, tularemia, and Epstein-Barr virus. Specific diagnosis typically requires a careful history, physical examination, and targeting serologic testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"       \"Etiologies of fever of unknown origin in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link\">",
"       \"Approach to the child with fever of unknown origin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Giardiasis and other intestinal parasites &ndash;",
"      </strong>",
"      Weight loss is a prominent symptom of both acute and chronic giardiasis. Acute disease is notable for nausea, vomiting, diarrhea, abdominal cramps, malaise, and flatulence. Chronic disease is marked by waxing and waning findings that include steatorrhea, malaise, fatigue, abdominal pain, flatulence, and burping. Patients with chronic giardiasis can lose up to 10 to 20 percent of their body weight. Stool microscopy is the initial diagnostic test of choice. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link&amp;anchor=H7#H7\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Children with a large burden of intestinal parasites other than Giardia may have weight loss and failure to thrive due to poor absorption of nutrients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=see_link\">",
"       \"Intestinal tapeworms\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=see_link\">",
"       \"Ascariasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Superior mesenteric artery syndrome",
"      </strong>",
"      &ndash; Superior mesenteric artery (SMA) syndrome is characterized by compression of the third portion of the duodenum due to narrowing of the space between the superior mesenteric artery and aorta. In children, SMA syndrome is associated with spinal surgery and is also more common in intellectually disabled patients who commonly present with intolerance of gastrostomy tube feedings [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30329/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients typically present with postprandial epigastric abdominal pain and early satiety, while those with more advanced obstruction may have severe nausea, bilious emesis and weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30329/abstract/5\">",
"       5",
"      </a>",
"      ]. Physical examination findings are often nonspecific but may include abdominal distension, a succussion splash, and high-pitched bowel sounds. Laboratory examination can be normal or, in patients with severe vomiting, significant electrolyte abnormalities may be present. Upper gastrointestinal fluoroscopy with small bowel follow through is diagnostic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37799?source=see_link\">",
"       \"Superior mesenteric artery syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cystic fibrosis",
"      </strong>",
"      &ndash; Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a complex chloride channel and regulatory protein found in all exocrine tissues. Deranged transport of chloride",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other CFTR-affected ions, such as sodium and bicarbonate, leads to thick, viscous secretions in the lungs, pancreas, liver, intestine, and reproductive tract, and to increased salt content in sweat gland secretions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H7#H7\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Overview of clinical features'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although screening for CF is performed in many resource-rich countries and most children otherwise present with signs or symptoms as infants, rarely older children and adolescents with intermediate derangements in CFTR may come to attention because of weight loss in association with frequent pneumonias, chronic cough, sinus disease, or pancreatic insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H7#H7\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Overview of clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cyclic vomiting",
"      </strong>",
"      &ndash; Cyclic vomiting syndrome (CVS) is an idiopathic disorder characterized by three or more recurrent discrete episodes of vomiting with varying intervals of completely normal health between episodes. Patients have no organic cause to their recurrent vomiting. The specific pattern of vomiting episodes is variable among patients but, importantly, is stereotypical for an individual patient. In general, CVS episodes tend to begin in the early morning hours (2:00 to 7:00 AM) and may involve a prodromal period of pallor, anorexia, nausea, abdominal pain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lethargy (",
"      <a class=\"graphic graphic_table graphicRef62483 \" href=\"UTD.htm?19/3/19516\">",
"       table 7",
"      </a>",
"      ). In children, the attacks last an average of 24 to 48 hours. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=see_link&amp;anchor=H11#H11\">",
"       \"Cyclic vomiting syndrome\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Supportive criteria for the diagnosis of CVS include a history or family history of migraine headaches, the self-limited nature of the attacks, associated symptoms of nausea, abdominal pain, headache, motion sickness, photophobia, and lethargy, and associated signs of fever, pallor, diarrhea, dehydration, excess salivation, and social withdrawal. In children, nausea and possibly lethargy are considered to be key diagnostic features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=see_link&amp;anchor=H11#H11\">",
"       \"Cyclic vomiting syndrome\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pancreatitis",
"      </strong>",
"      &ndash; Chronic pancreatitis should be considered in the differential diagnosis of children with growth failure, particularly those with a weight deficit and malnutrition. Abdominal pain is the cardinal feature of chronic pancreatitis. However, the pain pattern varies among patients and tends to fluctuate during the course of the disease. The pain typically is epigastric, often radiates to the back, is often associated with nausea and vomiting, and may be relieved by sitting upright or leaning forward. The pain often is worse 15 to 30 minutes after eating, especially if fatty food is consumed. Early in the course of chronic pancreatitis, the pain may occur in discrete attacks; as the condition progresses, the pain tends to become more continuous. Findings of malabsorption (steatorrhea) and glucose intolerance (glycosuria, frank diabetes mellitus) may also be present. The examination is often normal, but may include epigastric or upper abdominal tenderness. An epigastric mass may be palpated if the patient has developed a pseudocyst. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28616?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of chronic pancreatitis in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The diagnosis of chronic pancreatitis is relatively straightforward and can be suspected clinically in patients who present with acute pancreatitis followed by recurring attacks of pain. Diagnosis is more challenging in those with few or mild symptoms. In such patients, the diagnosis depends upon the strength of clinical features, combined with functional and morphologic evaluation of the pancreas, as described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28616?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of chronic pancreatitis in children\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Liver disease",
"      </strong>",
"      &ndash; Hepatic insufficiency with jaundice, anorexia, weakness, and malabsorption of fat may lead to weight loss in children. Right upper quadrant abdominal pain, hepatosplenomegaly, ascites, and encephalopathy are frequently present. Viral and drug-induced hepatitis, immune dysregulation, and rarely, Wilson disease comprise potential etiologies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link&amp;anchor=H18338289#H18338289\">",
"       \"Acute liver failure in children: Etiology and evaluation\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link&amp;anchor=H18338296#H18338296\">",
"       \"Acute liver failure in children: Etiology and evaluation\", section on 'Causes of pediatric acute liver failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Rheumatologic disease",
"      </strong>",
"      &ndash; Untreated collagen vascular diseases (eg, systemic lupus erythematosus, juvenile idiopathic arthritis) increase metabolic requirements and may present with weight loss. Associated findings include fever, characteristic rash (butterfly malar or evanescent macular papular rash), arthralgia or arthritis, elevated inflammatory markers (erythrocyte sedimentation rate or C-reactive protein), leukocytosis, and anemia.",
"     </li>",
"     <li>",
"      <strong>",
"       Hyperthyroidism",
"      </strong>",
"      &ndash; Hyperthyroidism in children and adolescents has unique effects on growth and development. Children will often have delayed growth plate closure with a subsequent increase in growth rate. This leads children to cross growth percentiles upwards for height in the setting of a significant weight loss. Other clinical features include lid lag and stare, diffuse goiter, tachycardia, increased gastrointestinal motility, proximal muscle weakness, tremor, hyper-reflexia, sleep disturbance, and distractibility. Diagnosis is made by measurement of serum thyroid function tests. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\", section on 'Growth'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypercalcemia",
"      </strong>",
"      &ndash; Hypervitaminosis D, hyperparathyroidism, myositis ossificans in patients with dermatomyositis, adverse effects of medications (eg, thiazide diuretics or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"       lithium",
"      </a>",
"      ) and, rarely malignancy are potential causes of hypercalcemia in children [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30329/abstract/6\">",
"       6",
"      </a>",
"      ]. Serum calcium levels &gt;12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      are associated with anorexia, abdominal pain, constipation, and nephrogenic diabetes insipidus manifested by polyuria and polydipsia. Patients may present with weight loss caused by dehydration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"       \"Clinical manifestations of hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lead poisoning",
"      </strong>",
"      &ndash; Marked elevation in blood lead above 60",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (2.9",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      may cause lead colic, which is marked by weight loss in association with sporadic vomiting, anorexia, abdominal pain, and constipation in a child with environmental exposure to lead. Measurement of a venous blood lead level is diagnostic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H10#H10\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Gastrointestinal'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      <strong>",
"       Sarcoidosis",
"      </strong>",
"      &ndash; Symptomatic sarcoidosis is rare in older children and adolescents. Presenting symptoms include pulmonary findings (cough, dyspnea, chest pain) and systemic symptoms of fever, anorexia, fatigue, and weight loss. Sarcoidosis has a myriad of extrapulmonary manifestations (",
"      <a class=\"graphic graphic_table graphicRef76046 \" href=\"UTD.htm?26/16/26892\">",
"       table 8",
"      </a>",
"      ). Diagnosis is supported by compatible clinical findings and radiographic features, exclusion of other diseases with similar presentation (eg, tuberculosis, lymphoma), and histopathology showing noncaseating granulomas in the lung (",
"      <a class=\"graphic graphic_picture graphicRef67837 \" href=\"UTD.htm?28/2/28710\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454894\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the evaluation of the child or adolescent with weight loss is to identify any signs and symptoms of underlying disease and then to explore potential psychosocial factors that may be involved. A careful, thorough history and physical examination, in conjunction with the judicious use of laboratory tests will often reveal the cause. Laboratory investigation is unlikely to reveal an organic cause in the absence of suggestive evidence from the initial history or physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454916\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should begin by determining the severity and acuity of weight loss:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute weight loss",
"      </strong>",
"      &ndash; Rapid weight loss is more indicative of a life-threatening process and needs prompt evaluation and treatment. Acute weight loss (usually less than one to two weeks in duration) is often caused by inadequate fluid and caloric intake, increased losses, or increased metabolic needs associated with an intercurrent illness.",
"      <br/>",
"      <br/>",
"      Key historical features suggest specific etiologies as follows (see",
"      <a class=\"local\" href=\"#H5454737\">",
"       'Life threatening conditions'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Polyuria and polydipsia (diabetes mellitus)",
"     </li>",
"     <li>",
"      Vomiting and weakness (adrenal insufficiency)",
"     </li>",
"     <li>",
"      Distorted body image with intentional weight loss (eating disorders)",
"     </li>",
"     <li>",
"      Significant fluid losses with lethargy and inadequate oral intake (dehydration)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chronic weight loss",
"      </strong>",
"      &ndash; Patients who have been experiencing weight loss over a longer period of time (usually greater than three weeks or via a slow progression) may have increased metabolic needs from underlying chronic disease, malabsorption, or other psychosocial stressors as contributing factors.",
"      <br/>",
"      <br/>",
"      The clinician should ask about any known medical conditions or changes in overall health. Changes in stool quality and quantity, the presence of blood in the stool, or changes to the diet may indicate malabsorption or inflammation (eg, celiac disease or inflammatory bowel disease). Unexplained fevers, malaise, or joint swelling should prompt the provider to consider rheumatologic or oncologic etiologies. Change in appetite, sleep, or school failure may indicate signs of depression.",
"      <br/>",
"      <br/>",
"      A family history should be completed specifically assessing for any relatives with malabsorption, gastrointestinal disease, malignancy, or eating disorders.",
"     </li>",
"     <li>",
"      <strong>",
"       Diet history",
"      </strong>",
"      &ndash; A complete diet history should be completed for all patients with particular attention to amount of daily intake, types of foods, recent changes (eg, fad dieting, change to vegetarianism, decreased appetite) or pica. A food intake diary can be helpful in cases where the exact intake may be over or under-estimated. The provider should note if weight loss began or progressed after introduction of specific foods (ie, gluten, dairy, or fats).",
"     </li>",
"     <li>",
"      <strong>",
"       Social history",
"      </strong>",
"      &ndash; Key elements of the social history include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History of frequent unintentional injuries, missed medical appointments, involvement of social services, or siblings with failure to thrive suggesting childhood neglect",
"     </li>",
"     <li>",
"      Frequent feelings of sadness, guilt, worthlessness or frequent thoughts of death or suicidal ideation as signs of depression",
"     </li>",
"     <li>",
"      Recreational drug use",
"     </li>",
"     <li>",
"      Amenorrhea, intense fear of gaining weight, or disturbed body image indicating an eating disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454923\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a complete physical examination, measurements of weight and, as appropriate, height should be documented on a standard growth chart and compared to any previous available measurements to assess for rate of loss and changes in weight percentile.",
"   </p>",
"   <p>",
"    Patients with signs of shock warrant prompt reversal of findings including support of airway and breathing, rapid vascular access, and rapid administration of isotonic intravenous fluids (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Physical findings that suggest potential etiologies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Body habitus",
"      </strong>",
"      &ndash; Weight for age and height defined as either 85 percent of that expected for age and height or a body mass index (BMI) &le;17.5 suggests an eating disorder (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       General appearance",
"      </strong>",
"      &ndash; Patients with celiac disease, child neglect, malnutrition, or eating disorders often appear wasted. Depressed patients often have a flat or sad affect. Pallor is frequently found in children with malignancy, especially leukemias, or rheumatologic disease (eg, systemic lupus erythematosus, SLE).",
"     </li>",
"     <li>",
"      <strong>",
"       Fever",
"      </strong>",
"      &ndash; Fever may be present in patients with infection, inflammatory bowel disease, rheumatologic disease, or malignancy.",
"     </li>",
"     <li>",
"      <strong>",
"       Heart rate &ndash;",
"      </strong>",
"      Tachycardia is common in patients with diabetic ketoacidosis, dehydration, hyperthyroidism, pancreatitis, and acute infections. Bradycardia is frequently found in patients with eating disorders.",
"     </li>",
"     <li>",
"      <strong>",
"       Compensated shock or hypotension",
"      </strong>",
"      &ndash; Tachycardia with prolonged capillary refill time or hypotension may occur in patients with diabetic ketoacidosis, adrenal insufficiency, dehydration, or serious acute infections.",
"     </li>",
"     <li>",
"      <strong>",
"       Tachypnea",
"      </strong>",
"      &ndash; Patients with diabetic ketoacidosis commonly display Kussmaul breathing, which is characterized more by deep than by rapid respirations. Findings of rales or wheezes suggest pneumonia in association with cystic fibrosis, human immunodeficiency virus infection, or tuberculosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Sinusitis &ndash;",
"      </strong>",
"      Sinus tenderness and discharge with sinusitis frequently occurs in children with cystic fibrosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Oral findings",
"      </strong>",
"      &ndash; Mucositis and oral ulcers may be seen in patients with inflammatory bowel disease. Hard palate lesions suggest rheumatologic disease. Patients with diabetic ketoacidosis have a fruity odor to their breath. Patients with frequent vomiting (eating disorder or cyclic vomiting) may have loss of enamel on the inside portion of the teeth.",
"     </li>",
"     <li>",
"      <strong>",
"       Goiter",
"      </strong>",
"      &ndash; Enlargement of thyroid gland is commonly seen in children with hyperthyroidism.",
"     </li>",
"     <li>",
"      <strong>",
"       Generalized lymphadenopathy",
"      </strong>",
"      &ndash; Cervical, axillary, and inguinal lymphadenopathy accompanies tuberculosis, human immunodeficiency virus infection, sarcoidosis, and malignancies.",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Abdominal tenderness &ndash;",
"      </strong>",
"      Diffuse tenderness suggests viral gastroenteritis, giardiasis, and inflammatory bowel disease. Epigastric tenderness and distension is frequently found in patients with pancreatitis or superior mesenteric artery syndrome.",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatosplenomegaly &ndash;",
"      </strong>",
"      Enlargement of the liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spleen may be found in patients with liver disease or malignancy.",
"     </li>",
"     <li>",
"      <strong>",
"       Rectal findings",
"      </strong>",
"      &ndash; Perianal skin tags and guaiac positive stool are potentially indicative of inflammatory bowel disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Joint findings",
"      </strong>",
"      &ndash; Joint effusions or pain with range of motion suggests rheumatologic disease or septic arthritis.",
"     </li>",
"     <li>",
"      <strong>",
"       Skin findings",
"      </strong>",
"      &ndash; Hyperpigmentation often accompanies adrenal insufficiency. Erythema nodosum may occur in patients with inflammatory bowel disease or sarcoidosis. Children with malignancy (especially leukemia) or child neglect may have bruising in areas that are not prone to trauma. Malar rash or evanescent salmon patches occur in patients with SLE and juvenile idiopathic arthritis, respectively.",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic findings",
"      </strong>",
"      &ndash; Diffuse weakness frequently occurs in patients with adrenal insufficiency and liver disease. Proximal weakness with hyperreflexia suggests hyperthyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454930\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no routine laboratory or radiographic evaluation for weight loss, and many patients with chronic weight loss require no testing in the emergency department. Further testing should be prompted by specific findings in the history and physical examination. (See",
"    <a class=\"local\" href=\"#H5454923\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies that may be warranted to initiate evaluation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      C- reactive protein",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Serum calcium and phosphorus",
"     </li>",
"     <li>",
"      Blood urea nitrogen and serum creatinine",
"     </li>",
"     <li>",
"      Rapid blood or serum glucose",
"     </li>",
"     <li>",
"      Serum total protein and albumen",
"     </li>",
"     <li>",
"      Serum lipase",
"     </li>",
"     <li>",
"      Serum aspartate and alanine aminotransferase",
"     </li>",
"     <li>",
"      Serum lactate dehydrogenase",
"     </li>",
"     <li>",
"      Serum uric acid",
"     </li>",
"     <li>",
"      Serum cortisol",
"     </li>",
"     <li>",
"      Ferritin",
"     </li>",
"     <li>",
"      Serum iron and iron-binding capacity",
"     </li>",
"     <li>",
"      Rapid human immunodeficiency virus testing",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone and thyroxine levels",
"     </li>",
"     <li>",
"      Serologic studies for celiac disease (ie, antiendomysial antibodies, tissue transglutamase (",
"      <a class=\"graphic graphic_algorithm graphicRef62181 \" href=\"UTD.htm?22/45/23250\">",
"       algorithm 2",
"      </a>",
"      ))",
"     </li>",
"     <li>",
"      Serologic studies for rheumatic disease (eg, antinuclear antibodies)",
"     </li>",
"     <li>",
"      Stool guaiac",
"     </li>",
"     <li>",
"      Stool for fat",
"     </li>",
"     <li>",
"      Bacterial cultures of stool",
"     </li>",
"     <li>",
"      Stool for ova and parasites",
"     </li>",
"     <li>",
"      Urine dipstick for glucose and ketones",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Chest radiograph (AP and lateral)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454937\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table summarizes the causes of weight loss in children and adolescents, highlighting the most common and the most life threatening causes (",
"    <a class=\"graphic graphic_table graphicRef87727 \" href=\"UTD.htm?32/6/32876\">",
"     table 1",
"    </a>",
"    ). The approach to the evaluation of weight loss in older children and adolescent is summarized in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef87725 graphicRef87726 \" href=\"UTD.htm?17/63/18422\">",
"     algorithm 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3942355\">",
"    <span class=\"h2\">",
"     Acute weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessments of the degree and acuity of the weight loss along with specific historical and physical findings should guide the evaluation of these patients. Children and adolescents with acute weight loss who are ill, have signs of significant dehydration, or shock warrant rapid support of airway, breathing, and circulation (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 4",
"    </a>",
"    ). Further features that suggest specific etiologies include (",
"    <a class=\"graphic graphic_algorithm graphicRef87725 \" href=\"UTD.htm?35/32/36367\">",
"     algorithm 3A",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Glycosuria and ketonuria",
"      </strong>",
"      &ndash; Diabetic ketoacidosis (diabetes mellitus)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypoglycemia, hyperkalemia, and hyperpigmentation",
"      </strong>",
"      &ndash; Adrenal insufficiency",
"     </li>",
"     <li>",
"      <strong>",
"       Vomiting without diarrhea with history of stereotypical episodes",
"      </strong>",
"      &ndash; Cyclic vomiting",
"     </li>",
"     <li>",
"      <strong>",
"       Short duration of fever with vomiting and diarrhea",
"      </strong>",
"      &ndash; Acute gastroenteritis",
"     </li>",
"     <li>",
"      <strong>",
"       Polyuria, polydipsia, constipation, and normal glucose",
"      </strong>",
"      &ndash; Hypercalcemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3942417\">",
"    <span class=\"h2\">",
"     Chronic weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features that help differentiate among the various causes of chronic weight loss in children and adolescents include (",
"    <a class=\"graphic graphic_algorithm graphicRef87726 \" href=\"UTD.htm?33/48/34562\">",
"     algorithm 3B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prolonged fever",
"      </strong>",
"      &ndash; Fever longer than one to two weeks of duration suggests chronic infection (eg, tuberculosis, human immunodeficiency virus), rheumatic disease (eg, systemic lupus erythematosus), inflammatory bowel disease, or malignancy.",
"     </li>",
"     <li>",
"      <strong>",
"       Abdominal pain without fever",
"      </strong>",
"      &ndash; Potential diagnoses include liver disease, lead poisoning, inflammatory bowel disease, giardiasis, celiac disease, lactose intolerance, superior mesenteric artery syndrome, and pancreatitis.",
"     </li>",
"     <li>",
"      <strong>",
"       Neither fever nor abdominal pain",
"      </strong>",
"      &ndash; Chronic weight loss in patients who have no history of fever or abdominal pain may be caused by cystic fibrosis, diabetes mellitus, adrenal insufficiency, hyperthyroidism, malnutrition, child abuse and neglect, eating disorder, depression, or drug use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5454944\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The causes of weight loss in older infants, children, and adolescents are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef87727 \" href=\"UTD.htm?32/6/32876\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5454730\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants, children and adolescents with acute weight loss who are ill, have signs of significant dehydration, or shock warrant rapid support of airway, breathing, and circulation (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"       algorithm 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3942355\">",
"       'Acute weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessments of the degree and acuity of the weight loss along with specific historical and physical findings help to identify specific etiologies and the diagnostic approach as shown in the algorithms (",
"      <a class=\"graphic graphic_algorithm graphicRef87725 graphicRef87726 \" href=\"UTD.htm?17/63/18422\">",
"       algorithm 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5454894\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5454937\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tunnessen WW, Roberts KB. Weight loss. In: Signs and Symptoms in Pediatrics, 3rd edition, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.36.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30329/abstract/2\">",
"      Block RW, Krebs NF, American Academy of Pediatrics Committee on Child Abuse and Neglect, American Academy of Pediatrics Committee on Nutrition. Failure to thrive as a manifestation of child neglect. Pediatrics 2005; 116:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30329/abstract/3\">",
"      Kirkpatrick SI, McIntyre L, Potestio ML. Child hunger and long-term adverse consequences for health. Arch Pediatr Adolesc Med 2010; 164:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30329/abstract/4\">",
"      Geskey JM, Erdman HJ, Bramley HP, et al. Superior mesenteric artery syndrome in intellectually disabled children. Pediatr Emerg Care 2012; 28:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30329/abstract/5\">",
"      Gerasimidis T, George F. Superior mesenteric artery syndrome. Wilkie syndrome. Dig Surg 2009; 26:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30329/abstract/6\">",
"      Benjamin RW, Moats-Staats BM, Calikoglu's A, et al. Hypercalcemia in children. Pediatr Endocrinol Rev 2008; 5:778.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16377 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30329=[""].join("\n");
var outline_f29_39_30329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5454944\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5454716\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25288663\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5454723\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5454730\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5454737\">",
"      Life threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454745\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454752\">",
"      - Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454766\">",
"      - Eating disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4101546\">",
"      - Dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5454787\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2085889\">",
"      - Viral gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12161442\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454780\">",
"      - Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454795\">",
"      - Acute infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454809\">",
"      - Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454816\">",
"      - Child neglect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5454823\">",
"      - Malnutrition and failure to thrive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2085988\">",
"      - Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2086096\">",
"      - Drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5454830\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5454894\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5454916\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5454923\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5454930\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5454937\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3942355\">",
"      Acute weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3942417\">",
"      Chronic weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5454944\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/16377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16377|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/61/2000\" title=\"algorithm 1\">",
"      Undifferentiated pediatric shock algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/45/23250\" title=\"algorithm 2\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/32/36367\" title=\"algorithm 3A\">",
"      Algorithm for acute weight loss in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/48/34562\" title=\"algorithm 3B\">",
"      Algorithm for chronic weight loss in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/12/42178\" title=\"algorithm 4\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16377|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/31/8703\" title=\"figure 1\">",
"      Rela incid immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16377|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/2/28710\" title=\"picture 1\">",
"      Transbronchial biopsy sarcoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16377|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/6/32876\" title=\"table 1\">",
"      Causes of weight loss in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/7/9339\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/12/29901\" title=\"table 4\">",
"      FTT pathophysiologic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/0/12299\" title=\"table 5\">",
"      Causes of lactose malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/4/3149\" title=\"table 6\">",
"      Clinical features of immunodeficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/3/19516\" title=\"table 7\">",
"      Features CVS children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/16/26892\" title=\"table 8\">",
"      Sarcoid organ involvement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=related_link\">",
"      Acute liver failure in children: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=related_link\">",
"      Ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27238?source=related_link\">",
"      Causes and clinical manifestations of central adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28616?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=related_link\">",
"      Cyclic vomiting syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31749?source=related_link\">",
"      Epidemiology of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=related_link\">",
"      Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=related_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=related_link\">",
"      Intestinal tapeworms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37799?source=related_link\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1737?source=related_link\">",
"      The adolescent with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=related_link\">",
"      Treatment of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_39_30330="Alternative renal replacement therapies in end-stage renal disease";
var content_f29_39_30330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alternative renal replacement therapies in end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30330/contributors\">",
"     Andreas Pierratos, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30330/contributors\">",
"     Gihad E Nesrallah, MD, FRCPC, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30330/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/39/30330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/39/30330/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/39/30330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite improvements in technology and patient care, the mortality rate of patients on maintenance dialysis remains alarmingly high, at approximately 15 to 20 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In an attempt to improve outcomes, it was postulated that a higher dialysis dose than commonly provided during conventional dialysis may increase survival among patients undergoing renal replacement therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this hypothesis was refuted in two large well-designed studies in both hemodialysis and peritoneal dialysis patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The HEMO study failed to show a positive effect on patient survival when dialysis dose per hemodialysis session was increased above the current",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      recommendations [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"       \"Kt/V and the adequacy of hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the ADEMEX study, no decrease in mortality was seen with peritoneal dialysis doses greater than a weekly",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.7 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"       \"Adequacy of peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the wake of these negative studies, significant attention has turned to alternative dialysis schedules, such as long, intermittent hemodialysis (HD), short-daily HD, and nocturnal HD. Each of these approaches is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, new and innovative forms of renal replacement therapy for patients undergoing maintenance therapy have also emerged. These include hemodiafiltration, sorbent HD, and the use of bioartificial membranes. These alternative approaches to the treatment of end-stage renal disease (ESRD) will be discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF UREMIC TOXINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To better understand the possible role for alternative renal replacement therapies, it is worthwhile to briefly review the physical properties of known uremic toxins and how effectively conventional hemodialysis removes these substances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Uremic toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uremic syndrome results largely from the accumulation of toxins in those with ESRD, which include molecules that are normally filtered, excreted, or catabolized by the normal kidney. Of the large number of solutes retained in renal failure, at least 90 of the identified compounds may be toxic.",
"   </p>",
"   <p>",
"    Solutes can be divided into the following general categories [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low molecular weight (MW) toxins (MW &lt;500 D)",
"     </li>",
"     <li>",
"      Middle MW toxins (500 to 15,000 D), referred to collectively as middle molecules (MM)",
"     </li>",
"     <li>",
"      Large solutes (&gt;15,000 D), frequently classified as large molecular weight proteins (LMWP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low molecular weight molecules, exemplified by urea, contribute to the uremic syndrome since uremic symptoms are improved with conventional hemodialysis using low flux membranes that principally remove such toxins. In addition, the clearance of urea (as measured by",
"    <span class=\"nowrap\">",
"     Kt/Vurea)",
"    </span>",
"    correlates with patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The question of the relative contributions of retained middle molecules to uremic symptoms has been debated. However, there is little doubt that several of these compounds are toxic (beta-2-microglobulin, parathyroid hormone [PTH], and others). Beta-2 microglobulin levels, for example, are associated with the development of dialysis-related amyloidosis (DRA) and possibly reduced survival. It seems likely that beta-2 microglobulin is a marker for overall middle-molecule clearance, including more toxic and as yet unidentified solutes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lastly, evidence is accumulating that larger or protein-bound toxins contribute to the high prevalence of cardiovascular disease in ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Toxin removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solute removal during conventional hemodialysis occurs by three different mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Passive diffusion down a favorable concentration gradient",
"     </li>",
"     <li>",
"      Convection, where the frictional forces between water and solutes results in the transport of small and large molecular weight solutes in the direction of ultrafiltration (ie, solvent drag)",
"     </li>",
"     <li>",
"      Adsorption of solutes to the dialysis membrane",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clearance of small solutes during conventional hemodialysis is dependent upon their size, as well as the concentration gradient across the dialysis membrane. As the molecular weight of a solute (including those that are protein bound) increases, removal by diffusion becomes less efficient.",
"   </p>",
"   <p>",
"    Removal of middle and large MW solutes depends upon their plasma concentration, molecular weight, protein binding, length of dialysis, membrane permeability, and the presence of convective transport. Convective dialysis regimens have therefore been developed to exploit the ability of convection to remove larger MW solutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONVECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of convective solute transport during dialysis depends upon the sieving coefficient of the solute for a given membrane and the ultrafiltration rate, which in turn depends on the transmembrane pressure (TMP). The sieving coefficient is the ratio of the concentration of the solute in the ultrafiltrate over the plasma. It ranges from 0 (no removal) to 1 (complete removal). As an example, the sieving coefficient for small molecules is 1, while the coefficient for beta-2-microglobulin is 0.6 across high flux membranes and approaches 1 with some of the newer membranes.",
"   </p>",
"   <p>",
"    Convective transport is also influenced by secondary membrane formation and concentration polarization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary membrane formation is related to the adsorption of proteins on the surface of the membrane and offers resistance to the transfer of both water and solutes.",
"     </li>",
"     <li>",
"      Concentration polarization constitutes a layer of increased concentration of a high molecular weight solute close to the membrane which is created as the specific solute is left behind during ultrafiltration due to its slower transfer rate. As this creates a concentration gradient and flux away from the membrane and towards the center of the hollow fiber, it impedes the convection of other solutes. At the same time, however, it increases the concentration gradient of that particular solute across the membrane, thereby facilitating its removal. Concentration polarization is more prominent with high ultra-filtration rates, low blood flow rates (less washout of the increased concentration layer), and the use of postdilution (rather than predilution) techniques (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High trans-membrane pressure (TMP) is necessary for convection to take place. The relationship between TMP and ultrafiltration is linear at moderate TMP levels. However, ultrafiltration plateaus or reverses at higher TMP, thereby decreasing the effectiveness while increasing the risk to the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemofiltration and hemodiafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For chronic renal replacement therapy, the two principal regimens used to provide substantial removal of larger MW uremic toxins via convection are intermittent hemofiltration (HF) and intermittent hemodiafiltration (HDF). Daily convective therapy has also been used. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Daily HF/HDF'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemofiltration &mdash; With HF, fluid is removed by the dialysis machine through increased transmembrane pressure and the replacement solution is infused intravenously at equal volume minus the desired fluid volume removal. The clearance of the method for a particular solute is dictated by the ultrafiltration volume and the sieving coefficient. As the sieving coefficient for low MW unbound solutes equals 1, the clearance for small molecules equals the ultrafiltrate volume. Although hemofiltration is effective in the removal of the larger MW solutes, it is less effective in the removal of small molecules as it is restricted by the ultrafiltration volume.",
"     </li>",
"     <li>",
"      Hemodiafiltration &mdash; HDF is a combination of hemodialysis and hemofiltration devised to overcome the low clearance of small solutes by hemofiltration by adding a diffusive component.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For chronic renal replacement therapy, the standard regimen for both HF and HDF includes three sessions per week for three to five hours, as with conventional intermittent hemodialysis. A typical conservative (or high dose) regimen for HDF includes a post dilution configuration with a blood flow of 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for high dose), a dialysate flow of 500",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    a flow of a substitution volume of 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (120",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for high dose) and a high flux dialyzer of 1.4 m(2) (2.2 m(2) for high dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous renal replacement therapies utilizing convection are also used in the intensive care setting for the treatment of acute renal failure. These modalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Methods of infusing replacement fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replacement fluid can be infused before (predilution mode) or after the dialyzer (postdilution mode) in both HF and HDF. More recently, a combination of the two configurations, mid-dilution, has been used with some success. A large ultrafiltrate volume is generated across a membrane with high hydraulic permeability.",
"   </p>",
"   <p>",
"    The relative benefits and limitations of each of these ways of replacing fluid are briefly discussed in the following sections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postdilution mode &mdash; In the postdilution mode, the ultrafiltration volume is limited by the ensuing hemoconcentration that occurs. As a result, a high blood flow rate is desirable. To avoid extreme hemoconcentration, which can lead to clotting and ultrafiltration failure, the filtration fraction should be limited to 50 percent. The filtration fraction is calculated as the ultrafiltration",
"      <span class=\"nowrap\">",
"       volume/plasma",
"      </span>",
"      water, which equals (blood flow rate) X (1 - Hematocrit).",
"      <br/>",
"      <br/>",
"      Another limitation of the post dilutional technique is the risk of albumin loss as well as the risk from the increased transmembrane pressure needed to achieve the desired UF volume. High TMP can decrease ultrafiltration (see above) and can lead to fiber rupture. TMP should be kept well below 400 mmHg. Thus, the ultrafiltration limit depends upon the blood flow, hematocrit, and serum albumin. Usually only 20 to 25 liters can be removed during a four hour treatment.",
"     </li>",
"     <li>",
"      Predilution mode &mdash; The primary disadvantage of the predilution mode is a relative decrease in the clearance of both small molecules and LMWP. This is due to a reduction of the concentration gradient between the blood and the dialysate, which is caused by the infusion of the substitution solution.",
"      <br/>",
"      <br/>",
"      Thus, with the same ultrafiltration volumes, postdilution methods are superior to predilution methods for removal of all solutes, particularly the middle molecules and LMWP [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/12\">",
"       12",
"      </a>",
"      ]. In the predilution HDF mode, the UF volume and substitution fluid infusion rate can be as high as 400",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or 60 to 100 liters per session [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      To achieve similar convective clearance, approximately twice as much fluid is needed in predilution as in postdilution mode. Proponents of predilution HDF maintain that it is possible to use higher ultrafiltration rates, thereby increasing convective removal. It has been calculated that, unless the substitution fluid volume exceeds 200",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      the postdilution mode offers higher convective clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other disadvantages of the predilution mode are the increased possibility of exposure to microbial (or endotoxin) contamination and acetate [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/17\">",
"       17",
"      </a>",
"      ] and the financial impact of the larger volume of substitution fluid if on-line production of fluid solution is not used.",
"      <br/>",
"      <br/>",
"      The advantages of the predilution mode include the lack of restriction on ultrafiltration volume, as well as the avoidance of high transmembrane pressure and hemoconcentration, which could lead to clotting, albumin leakage, and membrane rupture as previously discussed.",
"     </li>",
"     <li>",
"      Middilution mode &mdash; The combination of pre- and postdilution has been employed to exploit the advantages and avoid the pitfalls of the two previous methods. This is usually achieved by the use of a special filter where the substitution solution is infused in the middle of the filter. Improved clearance as compared with the original techniques has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/18-23\">",
"       18-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Choice of infusion methods &mdash; A generally useful approach is to use predilution in HF and postdilution in HDF. This approach aims for the maximum volume of fluid exchange in both cases. When large volumes of ultrafiltrate are generated, choosing the right membrane and controlling the transmembrane pressure are important to avoid excess protein loss [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other configurations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different configurations have been employed to provide HF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HDF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemofiltration with backfiltration consists of two filters in series, one for fluid removal and one for fluid reinjection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the 'push-pull' HDF technique, the same filter is used for ultrafiltration and backfiltration sequentially [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. The amount of ultrafiltration has to be much higher to compensate for the time lost during backfiltration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For reasons explained in the next section, 'on-line' substitution fluid production is currently standard practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Substitution fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, sterile Ringer's lactate solution was used as a substitution fluid for hemodiafiltration. More recently, bicarbonate-based solutions have been adopted. With these solutions, acetate, which is sometimes used in acid concentrates, is converted in vivo into bicarbonate.",
"   </p>",
"   <p>",
"    Isotonic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    has also been used in",
"    <span class=\"nowrap\">",
"     HF/HDF",
"    </span>",
"    (so-called acetate-free biofiltration [AFB]), with small reports of improved hemodynamic stability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. However, the isotonic bicarbonate solutions are not in widespread use.",
"   </p>",
"   <p>",
"    As",
"    <span class=\"nowrap\">",
"     HF/HDF",
"    </span>",
"    evolved, greater volumes of substitution fluid were used. This resulted in greater costs, and growing concerns about microbiological contamination. This was particularly the case for backfiltration and push-pull hemofiltration techniques, in which dialysate crosses the membrane and the risk of exposing the patient to pyrogenic substances is increased.",
"   </p>",
"   <p>",
"    Thus, there arose a need to generate larger quantities of substitution fluid of higher purity. Subsequently, there has been growing interest in generating \"ultra-pure\" dialysate even for conventional hemodialysis. This is due to the growing recognition that exposure to bacterial components not only can cause pyrogenic reactions but also low-grade inflammation that may contribute to the atherosclerosis, malnutrition, and poor outcomes for dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The meaning of the term \"ultra-pure\" has evolved over the last two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/33\">",
"     33",
"    </a>",
"    ]. The microbiological standards adopted by the American Association for the Advancement of Medical Instrumentation (AAMI) for water for dialysis are &lt;200 colony forming units (CFU) and &lt;0.5 Endotoxin Units",
"    <span class=\"nowrap\">",
"     (EU)/mL.",
"    </span>",
"    The more stringent standards of the European Pharmacopoeia include &lt;100 CFU and &lt;0.25",
"    <span class=\"nowrap\">",
"     EU/mL",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Subsequent adopted definitions require &lt;0.1 CFU and &lt;0.03",
"    <span class=\"nowrap\">",
"     EU/mL",
"    </span>",
"    for a solution to be considered \"ultra-pure.\" As compared with standard dialysis fluid, this translates into a 3-fold logarithmic difference in bacterial content, and a 1-fold logarithmic difference in endotoxin content [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/33\">",
"     33",
"    </a>",
"    ]. Some investigators suggest an even lower number for CFU and endotoxin levels for the substitution fluid to be used for",
"    <span class=\"nowrap\">",
"     HF/HDF",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique of 'on-line' fluid production (initially termed cold sterilization) has allowed the production of an unlimited volume of \"pure\" substitution fluid at a cost close to that of dialysate for conventional hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/22,34,35\">",
"     22,34,35",
"    </a>",
"    ]. The first step of the process includes the filtration of the water after it is produced using the reverse osmosis technique. The water is then used for the production of dialysate. This step has also been adopted in several hemodialysis machines to produce dialysate of improved purity for hemodialysis. The second step includes further filtration of the dialysate. Finally, a third filtration by a disposable microfilter completes the creation of the substitution solution. The disposable microfilter is replaced at the end of dialysis. The dialysate prior to the last filtration is used for the diffusive element of HDF. The purity achieved using this approach has been repeatedly confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most dialysis systems, the substitution solution volume is subtracted from the produced total dialysate volume. Increasing ultrafiltration and the need for substitution solution volume therefore improves convective efficacy, but decreases the diffusive efficacy of the system. A balance between the two is needed.",
"   </p>",
"   <p>",
"    In 2007, the European Best Practice Guidelines for hemodialysis recommended that exchange volumes should be as high as possible, with safety issues a significant consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structure of membranes used for dialysis and hemofiltration has evolved over the years. Larger pore sizes have been evaluated, with a view to enhancing the removal of larger molecules; however, this ultimately led to albumin loss. Although loss of albumin can increase the removal of albumin bound solutes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/38\">",
"     38",
"    </a>",
"    ], it is undesirable during convective therapy.",
"   </p>",
"   <p>",
"    Newer technologies have led to the creation of asymmetrical membranes. This allows the removal of larger molecules (not including albumin), and molecules like phosphorus and beta-2-microglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, the need for a narrow fiber lumen to facilitate backfiltration (and therefore add a convective element to hemodialysis) was eliminated by the development and current availability of low-cost sterile replacement solutions at volumes that make backfiltration unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/40\">",
"     40",
"    </a>",
"    ]. The sieving coefficient of larger molecules using the newer membranes is higher than previous membranes, approaching that of the glomerular membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL EFFECTS OF CONVECTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three principal components of convective dialytic therapies that may result in improved clinical outcomes versus that observed with conventional hemodialysis techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The convective process is associated with increased removal of larger molecules",
"     </li>",
"     <li>",
"      The use of high flux biocompatible membranes decreases cytokine release [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The use of high quality ('ultrapure') dialysate is associated with decreased cytokine release and the introduction of fewer impurities [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some of these elements have also been adopted by high flux hemodialysis. As examples, high flux membranes are widely used in conventional hemodialysis and ultrapure dialysate is available at a minimal cost. In addition, with conventional HD, there is an element of convection through 'backfiltration' when high flux membranes with narrow fibers are used, although the degree of convective clearance is typically less with conventional hemodialysis.",
"   </p>",
"   <p>",
"    Thus, the differences between the diffusive and convective technologies have become somewhat blurred. This becomes an issue when designing studies to compare these modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Solute removal",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366747\">",
"    <span class=\"h3\">",
"     Urea and creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small molecule clearance is usually lower with hemofiltration, as it is limited by the ultrafiltration volume, when compared to conventional hemodialysis or hemodiafiltration. By comparison, small molecule removal is increased with the use of high-efficiency on-line HDF and can be similar or even higher than hemodialysis depending upon the volume of the replacement solution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In the European DOPPS study, for example, patients on high efficiency (15 to 24.9 L substitution fluid per session) thrice-weekly HDF had higher",
"    <span class=\"nowrap\">",
"     Kt/Vurea",
"    </span>",
"    levels than those on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366754\">",
"    <span class=\"h3\">",
"     Beta-2-microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with conventional dialysis, it is well documented that there is relatively better removal of beta-2-microglobulin through convective techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/11,13,48-52\">",
"     11,13,48-52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reduction ratio of beta-2-microglobulin is between 70 and 80 percent with postdilution HDF; by comparison, it is between 40 and 50 percent in high-flux HD. In one study, there were reductions in beta-2-microglobulin of 20, 60, and 75 percent per session with low-flux, high-flux hemodialysis, and online hemodiafiltration, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study examined the relative clearance of urea and beta-2-microglobulin while sequentially changing the treatment elements from initially high flux HD, to higher dialyzer surface area, then to a higher blood flow and finally adding hemodiafiltration [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/11\">",
"       11",
"      </a>",
"      ]. The increases in urea clearance (as compared with the initial high flux HD) with each change were 6, 40 and 18 percent, respectively, while the increases in beta-2-microglobulin clearance were 22, 16, and 75 percent. This clearly demonstrated that membrane surface area and convection are more important for large molecule clearance, while increased blood flows favor urea removal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite increased removal with HDF, there are conflicting results concerning the predialysis levels of beta-2-microglobulin with this modality. Some studies, for example, have found no change in predialysis level or no difference compared with the control group on high flux hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. This has been attributed to slow intercompartmental transfer of the solute [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies, however, have found a relative decrease in predialysis beta-2-microglobulin levels over time with HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/47,54,55\">",
"     47,54,55",
"    </a>",
"    ]. One randomized study compared low flux HD to HDF using ultrapure dialysate with both methods, while maintaining the same small molecule clearance over 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/55\">",
"     55",
"    </a>",
"    ]. No clinical parameter including morbidity, mortality, blood pressure, hypotensive episodes, hematocrit or EPO dose were different between the two groups. However, predialysis beta-2-microglobulin concentration was significantly lower on HDF.",
"   </p>",
"   <p>",
"    In a randomized crossover trial that included 69 patients, basal values of beta-2-microglobulin were significantly lower among patients treated with HDF compared with low flux HD (22 versus 34",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, total beta-2-microglobulin removal seems to be enhanced with HDF, although predialysis levels are not consistently reduced as compared with HD.",
"   </p>",
"   <p>",
"    As discussed below, a number of studies have clearly demonstrated enhanced beta-2-microglobulin removal with daily HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/52,56\">",
"     52,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366773\">",
"    <span class=\"h3\">",
"     Phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased phosphate control by convective techniques has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. In one study, although urea and creatinine clearance was similar with HDF and HD, phosphate clearance was higher on HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/57\">",
"     57",
"    </a>",
"    ]. In a second report, phosphate removal increased when patients were converted from HD to HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/58\">",
"     58",
"    </a>",
"    ]. There was slow phosphate mobilization from tissue compartments as predialysis serum phosphate levels did not change until a few months after the switch. In the randomized crossover trial cited above, serum phosphate levels were lower among patients treated with HDF compared with low flux HD (4.6 versus 5.0",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively), despite lower daily doses of the phosphate binding agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/47\">",
"     47",
"    </a>",
"    ]. Parathyroid hormone levels were also shown to be lower among HDF patients in this study (202 versus 228",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in HD patients). However since high flux membranes are almost universally used on conventional hemodialysis today, it is unclear if the improved results are related to the membrane characteristics or the use of convective techniques.",
"   </p>",
"   <p>",
"    Despite the beneficial effect on phosphate removal, patients undergoing convective therapy still require phosphate binders, although at possibly a lower dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366780\">",
"    <span class=\"h3\">",
"     Other molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of homocysteine and complement D factor are decreased with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/49,61\">",
"     49,61",
"    </a>",
"    ]. By comparison, there are conflicting data concerning the effect of HF on levels of leptin and AGEs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/49,61-64\">",
"     49,61-64",
"    </a>",
"    ]. There is also evidence that convective therapies are associated with less oxidative stress but no difference in inflammatory markers were found between HDF and low flux hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential beneficial clinical effects of these changes await further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL EFFECTS OF CONVECTIVE THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366787\">",
"    <span class=\"h3\">",
"     Hemodynamic stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proponents of convective therapies maintain that improved hemodynamic tolerance is a key advantage of these modalities over conventional HD. Many [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/14,15,67-69\">",
"     14,15,67-69",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/70-72\">",
"     70-72",
"    </a>",
"    ] , studies have supported this view. The best data are from a multicenter randomized trial that compared the frequency of symptomatic hypotension among long-term dialysis patients who were assigned to receive hemodialysis (n = 70), on-line predilution hemofiltration (n = 36), or online predilution hemodiafiltration (n = 40) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/69\">",
"     69",
"    </a>",
"    ]. At a median follow-up of 1.5 years, compared with hemodialysis, there was a reduction in risk of intradialytic hypotension for both hemofiltration (OR 0.69, 95% CI 0.51-0.92) and hemodiafiltration (OR 0.46, 95% CI, 0.33-0.63).",
"   </p>",
"   <p>",
"    Potential mechanisms for improved hemodynamic stability include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salt loading via substitution fluid administration (with a loss of relatively hypotonic fluid) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased core body temperature (as a result of infusion of large amounts of fluid of lower temperature) leading to vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      It has been suggested that ultrapure dialysate itself is associated with improved hemodynamic stability [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. This may be due to reduced vasodilatation because of the lack of inflammation or exposure to pyrogens [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, convective techniques may be associated with better intradialytic stability, although the benefit may not be due to convection itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366794\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there were claims in the older literature of better blood pressure control with convective therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], there are no convincing data from randomized controlled studies that convective therapies offer better blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366801\">",
"    <span class=\"h3\">",
"     Cardiac hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence on the effect of convective therapies on the regression of left ventricular hypertrophy. In a multicenter randomized controlled trial, predilution HF (18 patients) was associated with regression of LVH compared with the control group (16 patients) dialyzed using low flux HD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/80\">",
"     80",
"    </a>",
"    ]. In another randomized controlled trial of patients on low flux HD and predilution HF, there was no difference in cardiovascular parameters including left ventricular mass index (LVMI) over one year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/61\">",
"     61",
"    </a>",
"    ]. However, daily HDF may be associated with regression of LVMI, suggesting a benefit with increased frequency rather than increased convection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Daily HF/HDF'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14366808\">",
"    <span class=\"h3\">",
"     Hematological parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of convection-based regimens on anemia has been variable. Several non-randomized studies found either improvement in hemoglobin or a decrease in erythropoietin dose requirements on HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/13,82-84\">",
"     13,82-84",
"    </a>",
"    ]. By comparison, two randomized controlled trials failed to demonstrate any improvements in these parameters with HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/55,61\">",
"     55,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is conceivable that the use of ultrapure dialysate may reduce erythropoietin resistance by improving the cytokine profile [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/85\">",
"     85",
"    </a>",
"    ]. Favorable effects on serum levels of inflammatory molecules have been observed with ultrapure dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Several studies have demonstrated the need for lower doses of ESA (erythropoiesis stimulating agents) for maintenance of target hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. This beneficial effect, however, was not seen in a randomized controlled trial when low flux dialyzers were used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the beneficial effect of convective therapies on anemia control, beyond the benefits of the use of ultrapure dialysate, has not been proven. Larger studies are needed to better evaluate this particular outcome issue.",
"   </p>",
"   <p>",
"    Platelet activation, as measured by the expression of CD62p, was more pronounced and more protracted during HDF than during low flux HD in the ongoing CONTRAST study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/90\">",
"     90",
"    </a>",
"    ]. It is unclear if this has potentially negative effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with HD, quality of life (QOL) generally appears to be superior with convective therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/61,91,92\">",
"     61,91,92",
"    </a>",
"    ]. In one randomized controlled study, QOL based upon the Laupacis questionnaire improved on HF versus low flux HD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting data exists concerning the relative effect of convective therapies on nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/55,61\">",
"     55,61",
"    </a>",
"    ]. In one randomized controlled study, there was an increase in lean body mass and body weight over one year in those undergoing HF as compared to no change in the group undergoing low-flux HD, although the difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/61\">",
"     61",
"    </a>",
"    ]. In another study, there was no difference in body weight albumin, skin fold thickness or albumin between those undergoing low flux HD and HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/55\">",
"     55",
"    </a>",
"    ]. Therefore, further studies are needed to demonstrate improvement in the nutritional status on convective therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dialysis related amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with the convective therapies has not been shown to reduce the complications of dialysis related amyloidosis, such as carpal tunnel syndrome (CTS). However, at least one retrospective study has suggested that the use of high-flux membranes (versus low flux) with conventional HD, was associated with a lower risk of developing CTS over time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As yet, enhanced clearance via",
"    <span class=\"nowrap\">",
"     HF/HDF",
"    </span>",
"    has not translated into improvements in DRA. However, while awaiting more definitive evidence, we suggest the use of convective therapies, where available, for treating this condition. No evidence-based recommendations can yet be made as to what level of beta-2-microglobulin should be considered a threshold for initiating convective therapy, where available, for the management of this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hospitalization rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data describing hospitalization rates and length of stay with",
"    <span class=\"nowrap\">",
"     HF/HDF",
"    </span>",
"    have been reported. One study that followed 45 patients for two years on HDF failed to demonstrate any difference in hospitalization rates as compared with over 300 patients treated with HD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/70\">",
"     70",
"    </a>",
"    ], while another cross-over study showed fewer (8 versus 17) hospitalizations on convective therapy, as compared with HD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/31\">",
"     31",
"    </a>",
"    ]. Larger-scale studies will be required to address the impact of the convective therapies on hospitalization rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patient survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting results exist concerning the relative mortality with HD versus HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/46,55,70,81,92,94-97\">",
"     46,55,70,81,92,94-97",
"    </a>",
"    ]. The disparate results may be explained by differences in the delivered convection volume used in different studies. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CONTRAST study compared all-cause mortality and a composite outcome of major cardiovascular events between 358 patients assigned to online HDF and 356 patients assigned to low-flux HD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/98\">",
"       98",
"      </a>",
"      ]. At a mean follow-up of three years, intention-to-treat analysis detected no difference in either outcome. In addition, there was no apparent benefit of HDF in predefined subgroups including patients with diabetes, cardiovascular disease, increased dialysis vintage, low albumin or no residual kidney function.",
"      <br/>",
"      <br/>",
"      However, the lack of benefit of HDF may have been related to an inadequate delivered dose for many patients since the target convective volume of 24",
"      <span class=\"nowrap\">",
"       L/treatment",
"      </span>",
"      was not achieved in the majority of patients; the mean delivered volume was 21 L and, among one-third of patients, only 18 L or less. In support of this hypothesis, post hoc on-treatment analysis showed a decrease in mortality among HDF-treated patients who received the highest delivered convective volume (&gt;22 L) compared with the HD group, even after adjustment for potential confounders [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/99\">",
"       99",
"      </a>",
"      ]. A similar trend was observed for cardiovascular events although this did not reach statistical significance.",
"     </li>",
"     <li>",
"      In the Turkish On-Line Hemodiafiltration (OL-HDF) Study, 782 participants were randomly assigned to postdilution online HDF or to high-flux HD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/100\">",
"       100",
"      </a>",
"      ]. At a mean follow-up of 23 months, there was no difference between groups in the primary outcome, (which was a composite of death from any cause and nonfatal cardiovascular events), nor in cardiovascular and overall survival, hospitalization rate, and number of hypotensive episodes.",
"      <br/>",
"      <br/>",
"      As in the CONTRAST study, the achieved convection volume varied between subjects, and the mean delivered volume was 21",
"      <span class=\"nowrap\">",
"       L/session",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/101,102\">",
"       101,102",
"      </a>",
"      ]. A post hoc subgroup analysis of patients treated with a median substitution volume &gt;17.4 L per session had better cardiovascular and overall survival compared with the high-flux HD group.",
"      <br/>",
"     </li>",
"     <li>",
"      The On-Line Hemodiafiltration Survival Study) included 906 chronic hemodialysis patients who were randomly assigned to on-line HDF or to continued HD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/103\">",
"       103",
"      </a>",
"      ]. Compared with those assigned to HD, patients assigned to online HDF had a lower risk of all-cause mortality (hazard ratio [HR] 0.70, 95% CI 0.530-0.92), infection-related mortality (HR 0.45, 95% CI 0.21&ndash;0.96), and cardiovascular mortality (HR 0.67, 95% CI 0.44&ndash;1.20). The mean delivered convection volume was 24",
"      <span class=\"nowrap\">",
"       L/session,",
"      </span>",
"      which is higher than that in either the CONTRAST or OL-HDF trials cited above. Thirty nine percent of patients withdrew from the study for various reasons, reducing overall confidence in the treatment effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In sum, compared with HD, HDF appears to provide a survival benefit if adequate convection volumes can be delivered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/102\">",
"     102",
"    </a>",
"    ]. At this time, however, convective therapies are rarely if ever used for chronic renal replacement therapy in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Trends in utilization of convective techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utilization of convective therapies has been variable. Between 1998 and 2001 about 12 percent of patients were on HDF in the European countries participating in the DOPPS study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There remains almost no utilization of intermittent convective therapies for chronic renal replacement therapy in North America. The reason for the lack of penetration in North America is a combination of a more complicated technology, lack of randomized controlled trials showing improved patient survival with convective therapies, and financial factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the failure of the HEMO study to show improvement in patient survival on higher dose HD may give some impetus for the use of alternate technologies including HDF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/4,105\">",
"     4,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cost of providing convective therapies has decreased with the availability of the on-line substitution fluid production, there no cost or cost-effectiveness data available comparing the convective techniques with conventional hemodialysis. Such data will likely be a necessary prerequisite for the widespread adoption of these techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The published literature suggests that there are benefits from the use of convective technologies. They include biochemical as well as clinical benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main biochemical benefits over conventional hemodialysis include enhanced clearance of middle molecules such as beta 2-microglobulin, as well as phosphate, and depending on the technique, other small molecules.",
"     </li>",
"     <li>",
"      The main clinical benefits include hemodynamic stability, possibly improved quality of life and a delay in the development of dialysis related amyloidosis. Benefits on anemia and blood pressure control are less well documented. Although cohort data indicate improved patient survival as compared to conventional hemodialysis, randomized controlled studies are still lacking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In practice environments with sufficient experience with these methods, they can be used as an alternative to conventional hemodialysis without much difficulty. Where available, it seems reasonable to use these therapies in the settings in which they are most likely to be beneficial, such as in patients with hemodynamic instability and possibly with dialysis-related amyloidosis.",
"   </p>",
"   <p>",
"    In North America, where experience with the convective therapies is still fairly limited, it appears that more rigorous studies will be required before these therapies will be adopted on a larger scale. Lack of familiarity and appropriate training are also likely barriers to more widespread use.",
"   </p>",
"   <p>",
"    Prospective randomized controlled studies with end points including patient survival, quality of life and cardiovascular parameters as well as studies on cost effectiveness are needed to facilitate adoption of the technique. Patients on convective techniques need to be compared to control groups on conventional hemodialysis using the best current practices. These should include the use of biocompatible dialyzers and ultrapure dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DAILY HF/HDF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not commonly performed for chronic therapy, daily convective therapy may provide significant benefits. Based upon theoretical models and calculations in different studies, some conclusions may be inferred regarding the relative clearance of different substances with daily convective therapy. In one study, a theoretical model was developed to predict dialysis dosing offered by short daily hemofiltration using 15 L of replacement solution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/106\">",
"     106",
"    </a>",
"    ]. This choice of fluid volume was made to allow for financially sustainable use of hemofiltration on a daily basis using a prepackaged solution at home.",
"   </p>",
"   <p>",
"    They used either EKR (equivalent renal urea clearance) or",
"    <span class=\"nowrap\">",
"     stdKt/V",
"    </span>",
"    as the dose measure for different MW solutes (urea, creatinine, vitamin B12, inulin, and beta-2-microglobulin) and for different therapies (conventional high flux HD, short daily HF, short daily HD, CAPD and daily nocturnal HD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. Results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When",
"      <span class=\"nowrap\">",
"       stdKt/V",
"      </span>",
"      was used as a dialysis dose measure for small molecules, daily HF was equivalent to conventional HD and CAPD but inferior to short daily HD and nocturnal HD.",
"     </li>",
"     <li>",
"      When",
"      <span class=\"nowrap\">",
"       stdKt/V",
"      </span>",
"      as a dialysis dose measure was used for the larger molecules, HF was better than all the regimens except for nocturnal HD.",
"     </li>",
"     <li>",
"      When EKR was used, daily HF was inferior to conventional or daily HD for small molecules but still better for larger molecules.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second study, seven times per week hemofiltration (at two hours per session) was required to achieve a predialysis urea similar to that achieved with hemodialysis performed thrice weekly for four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/109\">",
"     109",
"    </a>",
"    ]. This is consistent with the lower small molecule clearance offered by HF when compared to hemodialysis. However, a six times a week two hour session would provide lower pretreatment beta-2-microglobulin levels than three times a week hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies using daily",
"    <span class=\"nowrap\">",
"     HF/HDF",
"    </span>",
"    have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/52,56,110-113\">",
"     52,56,110-113",
"    </a>",
"    ]. Some of the measured outcomes included beta-2-microglobulin levels, blood pressure control, quality of life, phosphate control, and growth in children. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study that addressed the short term effects of daily HF reported that predialysis beta-2-microglobulin levels decreased by 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study in which 12 patients switched from HD to HF at home on a daily basis for one month, HF was associated with a lower blood pressure, higher caloric intake, and improved quality of life, findings consistent with previous reports on short daily HD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/111,113\">",
"       111,113",
"      </a>",
"      ]. A trend toward a decrease in serum beta-2-microglobulin could be safely ascribed to the HF alone. The infusion volume used was 40 percent of total body water, which offered a standard",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of approximately 2.0.",
"     </li>",
"     <li>",
"      In another study of eight patients undergoing in center daily hemodiafiltration for six months, there were lower serum levels of predialysis BUN and creatinine (which were expected by the change to a daily schedule), as well as lower levels of other solutes including beta-2-microglobulin and homocysteine [",
"      <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/56\">",
"       56",
"      </a>",
"      ]. Additional benefits included improved phosphate control, discontinuation of all antihypertensive agents, and a 30 percent regression in left ventricular mass. Although some of these results can be attributed to the daily treatment schedule, the decrease in the pretreatment levels of beta-2-microglobulin and the improvement in phosphate control are clearly attributable to both convection and the increased treatment frequency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Daily HDF has been used successfully in children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/114\">",
"     114",
"    </a>",
"    ]. Clinical results have been positive, including a strikingly favorable effect on growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SORBENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest sorbent technologies developed in the 1960s relied primarily upon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , which needed to be separated from the blood compartment due to its incompatibility with blood. Since clearance of water, urea, and inorganic ions was limited, it could only be used as an adjunct to dialysis.",
"   </p>",
"   <p>",
"    Dialysate regeneration and more elaborate sorbent systems had evolved by the 1970s in the form of the REDY system (REcirculating DialYsis System) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/115\">",
"     115",
"    </a>",
"    ]. Uremic solutes were metabolized or adsorbed by a sorbent cartridge. The main advantage of this method was that there was no need for water and it was portable. It has been used in the hospital setting as well as at home and when traveling. It represented the best choice for the military as well as in case of natural disasters when access to large volumes of water for dialysate production can be limited.",
"   </p>",
"   <p>",
"    The sorbent cartridge included five layers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An activated carbon layer, which adsorbed nitrogenous waste products",
"     </li>",
"     <li>",
"      A glucose hydrous zirconium layer which is an anion exchanger(acetate was exchanged for phosphate, fluoride and heavy metals)",
"     </li>",
"     <li>",
"      A zirconium phosphate layer which was a cation exchanger (Na+ and H+ were exchanged for ammonium, Ca+2, Mg+2 and K+)",
"     </li>",
"     <li>",
"      A urease layer (urease, bound to aluminum oxide, catalyzes the conversion of urea into ammonia and carbamic acid)",
"     </li>",
"     <li>",
"      A purification layer (activated carbon removes particulate matter, heavy metals and oxidizing substances).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the REDY system was eventually abandoned because of aluminum leaching, newer sorbents as well as a new and lightweight hemodialysis machine offer a promising comeback [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adsorption is a physico-chemical process where molecules are bound to sorbent particles or porous surfaces either through chemical or physical process. It is heavily dependent on pore structure. The pore size is divided into macro (&gt;500 A), meso (20 to 500 A), and micro (&lt;20 A) sizes.",
"   </p>",
"   <p>",
"    Removal of larger molecular weight substances has focused on sorbents containing mesopores.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    contains only a small number of mesopores compared to synthetic resin adsorbents which are the preferred materials.",
"   </p>",
"   <p>",
"    Newer sorbents have also been used in the form of a cartridge connected in series with a dialyzer to adsorb larger MW toxins such as beta-2-microglobulin, angiogenin, leptin and cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The Lixelle device (Kaneka Corp., Osaka, Japan) has been used in Japan to adsorb beta-2-microglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/119\">",
"     119",
"    </a>",
"    ]. Reduced symptoms of dialysis-related amyloidosis as well as a limited reduction in bone cysts on radiographs, short-lived reduction of inflammatory cytokines, endotoxin and peptidoglycans have been reported. The cost of the treatment using Lixelle is high ($300 per treatment). In Japan, coverage of this treatment is granted for up to one year. This sorbent device was also found to adsorb cytokines, endotoxin fragments and microbial fragments. Thus, it could be potentially of benefit to the septic patient in the intensive care unit. These uses are currently being explored [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although oral sorbents were considered in the treatment of ESRD in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/121-123\">",
"     121-123",
"    </a>",
"    ], no efficient commercial application exists to date. There is still interest in this area in the form of biochemically active microcapsules [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The future use of sorbents as an adjunct to the renal replacement therapy depends upon the clinical results from ongoing studies and on the added cost of this treatment. As yet, there does not appear to be a clearly defined role for this technology in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RENAL TUBULE ASSIST DEVICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal replacement therapy in its current forms does not replace the metabolic and endocrine functions of the renal tubular cells. In the setting of acute tubular necrosis, for example, proximal tubular function is lost. It is therefore desirable to provide not only the small solute clearance conferred by traditional dialytic modalities, but also some supportive cell function.",
"   </p>",
"   <p>",
"    Within the last decade, human proximal renal tubular cells have been successfully cultured on hollow fibre scaffolds, and a renal tubule cell assist device (RAD) used in series with a hemofiltration circuit has been created. This has been shown to replace metabolic, and endocrine functions, including improved acid-base balance (via glutamine metabolism), and activation of vitamin D, in acutely uremic dogs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/124\">",
"     124",
"    </a>",
"    ]. Its preliminary use in humans in the acute renal failure setting in the intensive care unit has been successful, adding hemodynamic stability and clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. Newer techniques to produce adequate numbers of tubular cells with longer survival may provide a solution to the technical constraints that prevent clinical utilization of the device [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness and safety of RAD therapy was evaluated in an open label phase II trial of 58 patients with acute renal failure who were randomly assigned (2:1 ratio) to receive RAD (up to 72 hours) plus continuous venovenous hemofiltration or continuous venovenous hemofiltration alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/128\">",
"     128",
"    </a>",
"    ]. There was a non-significant trend toward improved survival at 28 days (primary endpoint) with RAD plus continuous venovenous hemofiltration (67 versus 39 percent for continuous venovenous hemofiltration alone). Limitations of the study include low frequency of completion of the planned 72 hours of RAD, analysis of results as as-treated, inclusion of a large number of outcomes, and that the study was significantly underpowered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/129\">",
"     129",
"    </a>",
"    ]. Despite these flaws, this innovation may eventually represent a significant advance in the management of acute renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL TECHNOLOGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Wearable artificial kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prototype of a wearable artificial kidney utilizing an adsorption cartridge has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/130-133\">",
"     130-133",
"    </a>",
"    ]. It is worn as a belt, operated with batteries, and weighs less than five pounds. A hollow fiber dialyzer is used and dialysate is continuously regenerated by cartridges containing sorbents. In a pilot study using eight patients with end-stage real disease, the device was worn for four to eight hours, resulting in mean plasma urea and creatinine clearance rates of 23 and 21",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/131\">",
"     131",
"    </a>",
"    ]. The device was well tolerated, and clotting of the circuit was noted in two patients. Although the fistula needle was dislodged in one patient, there was no blood loss and treatment was continued. Effective clearance of beta2-microglobulin and phosphate was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A wearable bioartificial kidney combining continuous hemofiltration with cultured tubular epithelial cells on an artificial membrane may provide benefits. Current challenges in developing this technology include the long-term viability of cells and cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Artificial nephron system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Through the use of nanotechnology, a new 1 nm-thick membrane (T membrane) has been constructed that contains engineered pores that are highly specific for one type of molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?29/39/30330/abstract/134\">",
"     134",
"    </a>",
"    ]. T membranes with pores for all useful solutes are being constructed. The concept includes creation of an ultrafiltrate using a more traditional membrane. The T membrane reclaims all the useful molecules, while the rest are discarded in the drained ultrafiltrate. All of the useful molecules need to be identified with appropriate pores created that prevent them from being discarded. As it is a convective technique, dialysate is not necessary. The manufacturer anticipates the size of the portable device to be similar to the size of a large diver's watch and to be operating for 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Due largely to the strikingly high mortality rate of patients on conventional intermittent hemodialysis, significant attention has turned to new and innovative forms of renal replacement therapy. These principally include hemodiafiltration, sorbent hemodialysis, and the use of bioartificial membranes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Solute removal during conventional hemodialysis occurs by three different mechanisms: passive diffusion, adsorption of solutes to the dialysis membrane, and convection. Removal of middle and large molecular weight (MW) toxins depends upon certain characteristics, including convection. Convective dialysis regimens have therefore been developed to exploit the ability of convection to remove larger MW solutes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Toxin removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two principal regimens used to provide convection are intermittent hemofiltration (HF) and intermittent hemodiafiltration (HDF). Replacement fluid can be infused before (predilution mode) or after the dialyzer (postdilution mode) in both HF and HDF. A generally useful approach is to use predilution in HF and post dilution in HDF, aiming for the maximum volume of fluid exchange in both cases. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hemofiltration and hemodiafiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benefits with convective therapies, compared with conventional hemodialysis, are better removal of beta-2-microglobulin and improved hemodynamic stability. Convective therapies may provide a survival benefit if adequate convection volumes can be delivered. At this time, however, convective therapies are rarely if ever used for chronic renal replacement therapy in the United States. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with hemodynamic instability or dialysis related amyloidosis, we suggest the use of convective therapies, if available, rather than conventional intermittent hemodialysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical effects of convective therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sorbent technologies rely on a physico-chemical process where molecules are bound to sorbent particles or porous surfaces either through a chemical or physical process. Newer sorbents are used in the form of a cartridge connected in series with a dialyzer to adsorb larger MW toxins. The exact role for these technologies is unclear. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Sorbents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human proximal renal tubular cells have been successfully cultured on hollow fibre scaffolds. As a result, a renal tubule cell assist device used in series with a hemofiltration circuit has been created. This is the subject of an ongoing clinical trial. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Renal tubule assist device'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Experimental technologies include a wearable artificial kidney, artificial nephron system, and implantation of bioengineered cells. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Experimental technologies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/1\">",
"      USRDS: The United States Renal Data System: Overall hospitalization and mortality. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     USRDS. Morbidity and mortality. file://www.usrds.org (Accessed February 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/3\">",
"      Lowrie, E, Laird, NM. National Cooperative Dialysis Study. Kidney Int Suppl 1983; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/4\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/5\">",
"      Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/6\">",
"      Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/7\">",
"      Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/8\">",
"      Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: a new focus on an old subject. Semin Dial 2005; 18:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/9\">",
"      Vanholder R, Glorieux G, Lameire N, European Uremic Toxin Work Group. Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 2003; 18:463.",
"     </a>",
"    </li>",
"    <li>",
"     Huang, Z, Gao, D, Henderson, LW, Clark, WR. Hemofiltration and hemodiafiltration for end stage renal disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Companion To Brenner and Rector's The Kidney, 2nd edition, Pereira, BJG, Sayegh, MH, Blake, P, (Eds). Elsevier Saunders, Philadelphia 2006. p. 481.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/11\">",
"      Wizemann V, K&uuml;lz M, Techert F, Nederlof B. Efficacy of haemodiafiltration. Nephrol Dial Transplant 2001; 16 Suppl 4:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/12\">",
"      Ahrenholz P, Winkler RE, Ramlow W, et al. On-line hemodiafiltration with pre- and postdilution: a comparison of efficacy. Int J Artif Organs 1997; 20:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/13\">",
"      Maduell F, del Pozo C, Garcia H, et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/14\">",
"      Altieri P, Sorba GB, Bolasco PG, et al. On-line predilution hemofiltration versus ultrapure high-flux hemodialysis: a multicenter prospective study in 23 patients. Sardinian Collaborative Study Group of On-Line Hemofiltration. Blood Purif 1997; 15:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/15\">",
"      Altieri P, Sorba G, Bolasco P, et al. Predilution haemofiltration--the Second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long-term cross-over study. Nephrol Dial Transplant 2001; 16:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/16\">",
"      Colussi G, Frattini G. Quantitative analysis of convective dose in hemofiltration and hemodiafiltration: \"predilution\" vs. \"postdilution\" reinfusion. Hemodial Int 2007; 11:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/17\">",
"      Masakane I. Selection of dilutional method for on-line HDF, pre- or post-dilution. Blood Purif 2004; 22 Suppl 2:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/18\">",
"      Pedrini LA, De Cristofaro V, Pagliari B, Sam&agrave; F. Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes. Kidney Int 2000; 58:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/19\">",
"      Canaud B, L&eacute;vesque R, Krieter D, et al. On-line hemodiafiltration as routine treatment of end-stage renal failure: why pre- or mixed dilution mode is necessary in on-line hemodiafiltration today? Blood Purif 2004; 22 Suppl 2:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/20\">",
"      Krieter DH, Collins G, Summerton J, et al. Mid-dilution on-line haemodiafiltration in a standard dialyser configuration. Nephrol Dial Transplant 2005; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/21\">",
"      Krieter DH, Falkenhain S, Chalabi L, et al. Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration. Kidney Int 2005; 67:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/22\">",
"      Henderson LW, Beans E. Successful production of sterile pyrogen-free electrolyte solution by ultrafiltration. Kidney Int 1978; 14:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/23\">",
"      Feliciani A, Riva MA, Zerbi S, et al. New strategies in haemodiafiltration (HDF): prospective comparative analysis between on-line mixed HDF and mid-dilution HDF. Nephrol Dial Transplant 2007; 22:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/24\">",
"      Ledebo I. Convective dialysis therapies, current status and perspective. Ther Apher Dial 2005; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/25\">",
"      Shinzato T, Sezaki R, Usuda M, et al. Infusion-free hemodiafiltration: simultaneous hemofiltration and dialysis with no need for infusion fluid. Artif Organs 1982; 6:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/26\">",
"      Miwa M, Shinzato T. Push/pull hemodiafiltration: technical aspects and clinical effectiveness. Artif Organs 1999; 23:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/27\">",
"      Maeda K, Kobayakawa H, Fujita Y, et al. Effectiveness of push/pull hemodiafiltration using large-pore membrane for shoulder joint pain in long-term dialysis patients. Artif Organs 1990; 14:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/28\">",
"      Basile C, Giordano R, Montanaro A, et al. Effect of acetate-free biofiltration on the anaemia of haemodialysis patients: a prospective cross-over study. Nephrol Dial Transplant 2001; 16:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/29\">",
"      Schrander-vd Meer AM, ter Wee PM, Kan G, et al. Improved cardiovascular variables during acetate free biofiltration. Clin Nephrol 1999; 51:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/30\">",
"      Todeschini M, Macconi D, Fern&aacute;ndez NG, et al. Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am J Kidney Dis 2002; 40:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/31\">",
"      Verzetti G, Navino C, Bolzani R, et al. Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: a cross-over multicentric study. Nephrol Dial Transplant 1998; 13:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/32\">",
"      Stenvinkel P. Inflammation in end-stage renal disease--a fire that burns within. Contrib Nephrol 2005; 149:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/33\">",
"      Kjellstrand CM, Kjellstrand P. The ideal home hemodialysis machine. Hemodial Int 2008; 12 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/34\">",
"      Ledebo I. On-line hemodiafiltration: technique and therapy. Adv Ren Replace Ther 1999; 6:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/35\">",
"      Ledebo I. On-line preparation of solutions for dialysis: practical aspects versus safety and regulations. J Am Soc Nephrol 2002; 13 Suppl 1:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/36\">",
"      Vaslaki L, Kar&aacute;tson A, V&ouml;r&ouml;s P, et al. Can sterile and pyrogen-free on-line substitution fluid be routinely delivered? A multicentric study on the microbiological safety of on-line haemodiafiltration. Nephrol Dial Transplant 2000; 15 Suppl 1:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/37\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/38\">",
"      Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005; 16:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/39\">",
"      Ronco C, Crepaldi C, Brendolan A, et al. Evolution of synthetic membranes for blood purification: the case of the Polyflux family. Nephrol Dial Transplant 2003; 18 Suppl 7:vii10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/40\">",
"      Ronco C, Breuer B, Bowry SK. Hemodialysis membranes for high-volume hemodialytic therapies: the application of nanotechnology. Hemodial Int 2006; 10 Suppl 1:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/41\">",
"      Ghysen J, De Plaen JF, van Ypersele de Strihou C. The effect of membrane characteristics on tumour necrosis factor kinetics during haemodialysis. Nephrol Dial Transplant 1990; 5:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/42\">",
"      Canivet E, Lavaud S, Wong T, et al. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/43\">",
"      Schindler R, Lonnemann G, Sch&auml;ffer J, et al. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. Nephron 1994; 68:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/44\">",
"      Bommer J, Jaber BL. Ultrapure dialysate: facts and myths. Semin Dial 2006; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/45\">",
"      Canaud B, Bosc JY, Leblanc M, et al. Evaluation of high-flux hemodiafiltration efficiency using an on-line urea monitor. Am J Kidney Dis 1998; 31:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/46\">",
"      Canaud B, Bragg-Gresham JL, Marshall MR, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/47\">",
"      Pedrini LA, De Cristofaro V, Comelli M, et al. Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study. Nephrol Dial Transplant 2011; 26:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/48\">",
"      Lornoy W, Becaus I, Billiouw JM, et al. Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 1998; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/49\">",
"      Ward RA, Schmidt B, Hullin J, et al. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/50\">",
"      Shinzato T, Kobayakawa H, Maeda K. Comparison of various treatment modes in terms of beta 2-microglobulin removal: hemodialysis, hemofiltration, and push/pull HDF. Artif Organs 1989; 13:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/51\">",
"      Maduell F, Navarro V, Cruz MC, et al. Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis. Am J Kidney Dis 2002; 40:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/52\">",
"      Canaud B, Assounga A, Kerr P, et al. Failure of a daily haemofiltration programme using a highly permeable membrane to return beta 2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 1992; 7:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/53\">",
"      Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006; 69:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/54\">",
"      Lin CL, Yang CW, Chiang CC, et al. Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif 2001; 19:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/55\">",
"      Wizemann V, Lotz C, Techert F, Uthoff S. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant 2000; 15 Suppl 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/56\">",
"      Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 2003; 64:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/57\">",
"      Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration--a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999; 52:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/58\">",
"      Minutolo R, Bellizzi V, Cioffi M, et al. Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 2002; 13:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/59\">",
"      Penne EL, van der Weerd NC, van den Dorpel MA, et al. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 2010; 55:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/60\">",
"      Davenport A, Gardner C, Delaney M, Pan Thames Renal Audit Group. The effect of dialysis modality on phosphate control : haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. Nephrol Dial Transplant 2010; 25:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/61\">",
"      Beerenhout CH, Luik AJ, Jeuken-Mertens SG, et al. Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomized prospective study. Nephrol Dial Transplant 2005; 20:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/62\">",
"      Lin CL, Huang CC, Yu CC, et al. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003; 42:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/63\">",
"      Gerdemann A, Wagner Z, Solf A, et al. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002; 17:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/64\">",
"      Widjaja A, Kielstein JT, Horn R, et al. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease. Nephrol Dial Transplant 2000; 15:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/65\">",
"      Cal&ograve; LA, Naso A, Carraro G, et al. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 2007; 22:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/66\">",
"      Vaslaki LR, Berta K, Major L, et al. On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study. Artif Organs 2005; 29:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/67\">",
"      Mion M, Kerr PG, Argiles A, et al. Haemodiafiltration in high-cardiovascular-risk patients. Nephrol Dial Transplant 1992; 7:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/68\">",
"      Donauer J, Schweiger C, Rumberger B, et al. Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 2003; 18:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/69\">",
"      Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010; 21:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/70\">",
"      Locatelli F, Mastrangelo F, Redaelli B, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/71\">",
"      Karamperis N, Jensen D, Sloth E, Jensen JD. Comparison of predilution hemodiafiltration and low-flux hemodialysis at temperature-controlled conditions using high calcium-ion concentration in the replacement and dialysis fluid. Clin Nephrol 2007; 67:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/72\">",
"      Pinney JH, Oates T, Davenport A. Haemodiafiltration does not reduce the frequency of intradialytic hypotensive episodes when compared to cooled high-flux haemodialysis. Nephron Clin Pract 2011; 119:c138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/73\">",
"      Di Filippo, S, Manzoni, C, Andrulli, S, et al. Sodium removal during pre-dilution haemofiltration. Nephrol Dialys Transplant 2007; 18(Suppl7):vii31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/74\">",
"      Di Filippo S, Manzoni C, Andrulli S, et al. Sodium removal during pre-dilution haemofiltration. Nephrol Dial Transplant 2003; 18 Suppl 7:vii31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/75\">",
"      Karamperis N, Sloth E, Jensen JD. Predilution hemodiafiltration displays no hemodynamic advantage over low-flux hemodialysis under matched conditions. Kidney Int 2005; 67:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/76\">",
"      Kjellstrand, CM, Blagg, CR, Twardowski, ZJ, Bower, J. Cardiovascular stability (CVI) during daily hemodialysis (DHD) - Relative influence of dialysis purity, clearance and ultrafiltration speed - Experience with the Aksys PHD system. ASAIO J 2004; 50:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/77\">",
"      Kjellstrand, C, Blagg, C, Odar-Cederlof, I, et al. Daily hemodialysis (DHD) and ultrapure dialysis (UPH) synergistically improve patient well-being (WB) and cardiovascular stability (CVS). Hemodial Int 2007; 11:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/78\">",
"      Sch&uuml;nemann B, Girndt J, Quellhorst E. Hemofiltration as a treatment for \"dialysis-resistant\" hypertension and hypotensive hyperhydration. J Dial 1977; 1:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/79\">",
"      Kishimoto T, Yamagami S, Tanaka H, et al. Superiority of hemofiltration to hemodialysis for treatment of chronic renal failure: comparative studies between hemofiltration and hemodialysis on dialysis disequilibrium syndrome. Artif Organs 1980; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/80\">",
"      Alvestrand A, Ledebo I, Hagerman I, et al. Left ventricular hypertrophy in incident dialysis patients randomized to treatment with hemofiltration or hemodialysis: results from the ProFil study. Blood Purif 2011; 32:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/81\">",
"      Rabindranath KS, Strippoli GF, Daly C, et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev 2006; :CD006258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/82\">",
"      Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif 2002; 20:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/83\">",
"      Lin CL, Huang CC, Yu CC, et al. Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 2002; 20:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/84\">",
"      Vaslaki L, Major L, Berta K, et al. On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006; 24:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/85\">",
"      Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/86\">",
"      Guth HJ, Gruska S, Kraatz G. On-line production of ultrapure substitution fluid reduces TNF-alpha- and IL-6 release in patients on hemodiafiltration therapy. Int J Artif Organs 2003; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/87\">",
"      Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/88\">",
"      Kleophas W, Haastert B, Backus G, et al. Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. Nephrol Dial Transplant 1998; 13:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/89\">",
"      Lamas JM, Alonso M, Sastre F, et al. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study. Nephrol Dial Transplant 2006; 21:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/90\">",
"      Penne EL, Blankestijn PJ, Bots ML, et al. Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Semin Dial 2005; 18:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/91\">",
"      O'Loughlin JA, Bruder JM, Lysaght MJ. Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes. ASAIO J 2004; 50:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/92\">",
"      Lin CL, Huang CC, Chang CT, et al. Clinical improvement by increased frequency of on-line hemodialfiltration. Ren Fail 2001; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/93\">",
"      Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/94\">",
"      Rabindranath KS, Strippoli GF, Roderick P, et al. Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis 2005; 45:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/95\">",
"      Teo KK, Basile C, Ulan RA, et al. Comparison of hemodialysis and hypertonic hemodiafiltration on cardiac function [corrected]. Kidney Int 1987; 32:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/96\">",
"      Santoro A, Mancini E, Bolzani R, et al. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. Am J Kidney Dis 2008; 52:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/97\">",
"      Vilar E, Fry AC, Wellsted D, et al. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009; 4:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/98\">",
"      Grooteman MP, van den Dorpel MA, Bots ML, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/99\">",
"      Kuhlmann MK. On-line hemodiafiltration: not a self-fulfilling prophecy. J Am Soc Nephrol 2012; 23:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/100\">",
"      Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/101\">",
"      Blankestijn PJ. Haemodiafiltration: becoming the new standard? Nephrol Dial Transplant 2013; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/102\">",
"      Blankestijn PJ. Has the time now come to more widely accept hemodiafiltration in the United States? J Am Soc Nephrol 2013; 24:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/103\">",
"      Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/104\">",
"      Friedman EA. Birth and agony of hemofiltration. Am J Kidney Dis 2005; 45:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/105\">",
"      Levin N, Greenwood R. Reflections on the HEMO study: the American viewpoint. Nephrol Dial Transplant 2003; 18:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/106\">",
"      Leypoldt JK, Jaber BL, Lysaght MJ, et al. Kinetics and dosing predictions for daily haemofiltration. Nephrol Dial Transplant 2003; 18:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/107\">",
"      Lopot F, V&aacute;lek A. Time-averaged concentration--time-averaged deviation: a new concept in mathematical assessment of dialysis adequacy. Nephrol Dial Transplant 1988; 3:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/108\">",
"      Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13 Suppl 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/109\">",
"      Yamashita AC, Kawanishi H. Kinetics and dose of daily hemofiltration. Blood Purif 2004; 22 Suppl 2:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/110\">",
"      Zimmerman DL, Swedko PJ, Posen GA, Burns KD. Daily hemofiltration with a simplified method of delivery. ASAIO J 2003; 49:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/111\">",
"      Jaber BL, Zimmerman DL, Teehan GS, et al. Daily hemofiltration for end-stage renal disease: a feasibility and efficacy trial. Blood Purif 2004; 22:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/112\">",
"      Fischbach M, Terzic J, Laugel V, et al. Daily on-line haemodiafiltration: a pilot trial in children. Nephrol Dial Transplant 2004; 19:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/113\">",
"      Zimmerman, DL, Swedko, P, Posen, G, Burns, K. Daily hemofiltration with a simplified method of delivery. J Am Soc Nephrol 2002; 13:61A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/114\">",
"      Fischbach M, Terzic J, Menouer S, et al. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol Dial Transplant 2010; 25:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/115\">",
"      Lewin AJ, Greenbaum MA, Gordon A, Maxwell MH. Current status of the clinical application of the Redy R dialysate delivery system. Proc Clin Dial Transplant Forum 1972; 2:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/116\">",
"      Ash SR. The Allient dialysis system. Semin Dial 2004; 17:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/117\">",
"      Winchester JF. Sorbent hemoperfusion in end-stage renal disease: an in-depth review. Adv Ren Replace Ther 2002; 9:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/118\">",
"      Winchester JF, Salsberg JA. Sorbents in the treatment of renal failure. Minerva Urol Nefrol 2004; 56:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/119\">",
"      Kutsuki H. beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis. Biochim Biophys Acta 2005; 1753:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/120\">",
"      Tsuda K, Taniguchi T. Effects of extracorporeal treatment with Lixelle on the mortality and inflammatory responses to endotoxin-induced shock in rats. Ther Apher Dial 2006; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/121\">",
"      Yatzidis H, Oreopoulos D. Early clinical trials with sorbents. Kidney Int Suppl 1976; :S215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/122\">",
"      Yatzidis H, Koutsicos D, Digenis P. Newer oral sorbents in uremia. Clin Nephrol 1979; 11:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/123\">",
"      Friedman EA. Bowel as a kidney substitute in renal failure. Am J Kidney Dis 1996; 28:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/124\">",
"      Fissell WH, Lou L, Abrishami S, et al. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 2003; 14:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/125\">",
"      Humes HD, Weitzel WF, Bartlett RH, et al. Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure. Blood Purif 2003; 21:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/126\">",
"      Tiranathanagul K, Eiam-Ong S, Humes HD. The future of renal support: high-flux dialysis to bioartificial kidneys. Crit Care Clin 2005; 21:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/127\">",
"      Sanechika N, Sawada K, Usui Y, et al. Development of bioartificial renal tubule devices with lifespan-extended human renal proximal tubular epithelial cells. Nephrol Dial Transplant 2011; 26:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/128\">",
"      Tumlin J, Wali R, Williams W, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/129\">",
"      Chertow, GM, Waikar, SS. Toward the promise of renal replacement therapy. J Am Soc Nephrology 2008; 19:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/130\">",
"      Gura V, Beizai M, Ezon C, Rambod E. Continuous renal replacement therapy for congestive heart failure: the wearable continuous ultrafiltration system. ASAIO J 2006; 52:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/131\">",
"      Davenport A, Gura V, Ronco C, et al. A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet 2007; 370:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/132\">",
"      Gura V, Ronco C, Davenport A. The wearable artificial kidney, why and how: from holy grail to reality. Semin Dial 2009; 22:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/133\">",
"      Gura V, Davenport A, Beizai M, et al. Beta2-microglobulin and phosphate clearances using a wearable artificial kidney: a pilot study. Am J Kidney Dis 2009; 54:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/39/30330/abstract/134\">",
"      Nissenson AR, Ronco C, Pergamit G, et al. Continuously functioning artificial nephron system: the promise of nanotechnology. Hemodial Int 2005; 9:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1937 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30330=[""].join("\n");
var outline_f29_39_30330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF UREMIC TOXINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Uremic toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Toxin removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONVECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemofiltration and hemodiafiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Methods of infusing replacement fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other configurations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Substitution fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BIOCHEMICAL EFFECTS OF CONVECTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Solute removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366747\">",
"      - Urea and creatinine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366754\">",
"      - Beta-2-microglobulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366773\">",
"      - Phosphate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366780\">",
"      - Other molecules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL EFFECTS OF CONVECTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366787\">",
"      - Hemodynamic stability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366794\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366801\">",
"      - Cardiac hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14366808\">",
"      - Hematological parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dialysis related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hospitalization rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patient survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Trends in utilization of convective techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DAILY HF/HDF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SORBENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RENAL TUBULE ASSIST DEVICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      EXPERIMENTAL TECHNOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Wearable artificial kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Artificial nephron system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=related_link\">",
"      Uremic toxins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_39_30331="HIV associated myopathies";
var content_f29_39_30331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Myopathies associated with HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        HIV myopathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        NRTI myopathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxoplasma myopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Symptoms",
"       </td>",
"       <td>",
"        Myalgias, symmetric proximal muscle weakness",
"       </td>",
"       <td>",
"        Myalgias, symmetric proximal muscle weakness",
"       </td>",
"       <td>",
"        Diffuse muscle wasting, weakness, muscle tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Muscle enzymes",
"       </td>",
"       <td>",
"        Markedly elevated (up to ten-fold)",
"       </td>",
"       <td>",
"        Markedly elevated (up to ten-fold)",
"       </td>",
"       <td>",
"        Usually increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Electromyography",
"       </td>",
"       <td>",
"        Myopathic changes",
"       </td>",
"       <td>",
"        Mild myopathic changes or normal",
"       </td>",
"       <td>",
"        Similar to polymyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Muscle biopsy",
"       </td>",
"       <td>",
"        Mononuclear cell infiltrate",
"       </td>",
"       <td>",
"        Mitochondrial myopathy, no or mild inflammation, cytochrome C oxidase deficiency",
"       </td>",
"       <td>",
"        Necrosis, variable inflammation, intracellular cysts containing T. gondii organisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Treatment",
"       </td>",
"       <td>",
"        High dose corticosteroids",
"       </td>",
"       <td>",
"        Discontinue NRTI carnitine",
"       </td>",
"       <td>",
"        Pyrimethamine plus sulfadiazine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30331=[""].join("\n");
var outline_f29_39_30331=null;
var title_f29_39_30332="Echo views cardiac structures";
var content_f29_39_30332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51250%7ECARD%2F60909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51250%7ECARD%2F60909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used views to evaluate specific cardiac structures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Structure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Views",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left atrium",
"       </td>",
"       <td>",
"        PLA, PSA (base), apical 4-chamber, apical 2-chamber, apical 5-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricle",
"       </td>",
"       <td>",
"        PLA, PSA (mid/apical), apical 4-chamber, apical 2-chamber, apical 5-chamber, apical long axis,",
"subcostal 4-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right atrium",
"       </td>",
"       <td>",
"        Parasternal RV inflow, PSA (base), apical 4-chamber, apical 5-chamber, subcostal 4-chamber, subcostal short",
"axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricle",
"       </td>",
"       <td>",
"        PLA, PSA (mid/apical), apical 4-chamber, apical 5-chamber, subcostal 4-chamber, subcostal short axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending aorta",
"       </td>",
"       <td>",
"        PLA, PSA (base), apical long axis, apical 5-chamber, right parasternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transverse",
"aorta",
"       </td>",
"       <td>",
"        Suprasternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Descending",
"aorta",
"       </td>",
"       <td>",
"        PLA, PSA, subcostal, suprasternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interatrial septum",
"       </td>",
"       <td>",
"        PSA (base), apical 4-chamber, subcostal 4-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary",
"sinus",
"       </td>",
"       <td>",
"        PLA, RV inflow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial",
"effusion",
"       </td>",
"       <td>",
"        PLA, PSA, apical 4-chamber, subcostal 4-chamber",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PLA: parasternal long axis; PSA: parasternal short axis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used views to evaluate cardiac valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Valve",
"       </td>",
"       <td class=\"subtitle1\">",
"        View",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic valve",
"       </td>",
"       <td>",
"        PLA, PSA (base), apical long axis, apical 5-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve",
"       </td>",
"       <td>",
"        PLA, PSA (mid), apical long axis, subcostal 4-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricuspid valve",
"       </td>",
"       <td>",
"        Parasternal RV inflow, PSA (mid), apical 4-chamber, apical long axis, subcostal 4-chamber, subcostal short axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonic",
"valve",
"       </td>",
"       <td>",
"        Parasternal RV outflow, PSA (base), subcostal short axis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PLA: parasternal long axis; PSA: parasternal short axis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30332=[""].join("\n");
var outline_f29_39_30332=null;
var title_f29_39_30333="Treatment of relapsed WM";
var content_f29_39_30333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to the treatment of relapsed Waldenstr&ouml;m macroglobulinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 202px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WM: Waldenstr&ouml;m macroglobulinemia.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenstr&ouml;m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85:824. Copyright &copy; 2010 Quadrant HealthCom, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30333=[""].join("\n");
var outline_f29_39_30333=null;
var title_f29_39_30334="Twin rates by maternal age";
var content_f29_39_30334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Twin birth rate by age of mother: United States, 1980, 2000, and 2004",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 450px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: The twin birth rate is per 1000 live births. The birth rate for women aged 45-49 years for 1980 is not shown because of the small number of births.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Martin, J, Hamilton, B, Sutton, P, et al. Births: Final data for 2004. National Vital Statistics Reports 2006; 55:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30334=[""].join("\n");
var outline_f29_39_30334=null;
var title_f29_39_30335="TEE vena cavae bicaval view";
var content_f29_39_30335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Inferior and superior vena cavae, right atrium, and right atrial appendage on transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 186px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Using a vertical (90L) imaging plane, the superior vena cava (SVC), inferior vena cava (IVC), right atrial appendage (RAA), body of the right atrium (RA), interatrial septum, and left atrium (LA) are visualized (panel A). Panel B is a similar orientation during injection of agitated saline through the right antecubital vein. There is early appearance of contrast filling the superior vena cava and superior half of the right atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_39_30335=[""].join("\n");
var outline_f29_39_30335=null;
